primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
105717393,10571739,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4368015,,204042.0,,,CAPSULE,,2016,Q1,Prostate cancer,,2016,Q1,3,F,20140626.0,20160113.0,20141107,20160119,EXP,,US-JNJFOC-20141101354,JANSSEN,,69.0,YR,E,M,Y,79.83,KG,20160119.0,,MD,US,US,2016,Q1,Elderly
105717393,10571739,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 OR 300 MG,,,,N, 4368015,,76479.0,,,CAPSULE,,2016,Q1,Prostate cancer,,2016,Q1,3,F,20140626.0,20160113.0,20141107,20160119,EXP,,US-JNJFOC-20141101354,JANSSEN,,69.0,YR,E,M,Y,79.83,KG,20160119.0,,MD,US,US,2016,Q1,Elderly
109127334,10912733,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,,100.0,MG,TABLET,,2016,Q1,Removal of internal fixation,,2016,Q1,4,F,20150226.0,20160317.0,20150313,20160323,EXP,,JP-JNJFOC-20150305494,JANSSEN,,63.0,YR,A,M,Y,79.0,KG,20160323.0,,OT,JP,JP,2016,Q1,Adult
109127334,10912733,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q1,Removal of internal fixation,,2016,Q1,4,F,20150226.0,20160317.0,20150313,20160323,EXP,,JP-JNJFOC-20150305494,JANSSEN,,63.0,YR,A,M,Y,79.0,KG,20160323.0,,OT,JP,JP,2016,Q1,Adult
110711104,11071110,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Herpes zoster disseminated,,2016,Q1,4,F,20150410.0,20160317.0,20150428,20160323,PER,,JP-JNJFOC-20150419556,JANSSEN,,67.0,YR,E,M,Y,54.0,KG,20160323.0,,OT,JP,JP,2016,Q1,Elderly
112274868,11227486,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST WITH WATER,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Cerebral artery occlusion,,2016,Q1,8,F,20150617.0,20160324.0,20150630,20160331,EXP,,JP-JNJFOC-20150620341,JANSSEN,,58.0,YR,A,M,Y,79.0,KG,20160331.0,,OT,JP,JP,2016,Q1,Adult
112632794,11263279,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST WITH WATER,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Gastric cancer,,2016,Q1,4,F,20150703.0,20160226.0,20150712,20160304,EXP,,JP-JNJFOC-20150707343,JANSSEN,,74.0,YR,E,M,Y,52.0,KG,20160304.0,,OT,JP,JP,2016,Q1,Elderly
113265062,11326506,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Large intestine polyp,,2016,Q1,2,F,20150721.0,20160316.0,20150731,20160324,EXP,,JP-JNJFOC-20150722750,JANSSEN,,71.0,YR,E,M,Y,68.0,KG,20160324.0,,OT,JP,JP,2016,Q1,Elderly
113408973,11340897,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST WITH WATER,,,,N,,,204042.0,100.0,MG,CAPSULE,QD,2016,Q1,Chondrocalcinosis pyrophosphate,,2016,Q1,3,F,20150726.0,20160226.0,20150805,20160304,EXP,,JP-JNJFOC-20150800802,JANSSEN,,73.0,YR,E,F,Y,54.0,KG,20160304.0,,OT,JP,JP,2016,Q1,Elderly
113987476,11398747,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Colon cancer,,2016,Q1,6,F,20150721.0,20160316.0,20150820,20160323,EXP,,JP-JNJFOC-20150812230,JANSSEN,,65.0,YR,A,M,Y,72.0,KG,20160323.0,,MD,JP,JP,2016,Q1,Elderly
114321972,11432197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186106,,204042.0,,,CAPSULE,,2016,Q1,Cachexia,,2016,Q1,2,F,201507.0,20160204.0,20150828,20160212,EXP,,ES-JNJFOC-20150804226,JANSSEN,,61.0,YR,A,M,Y,65.0,KG,20160212.0,,MD,ES,ES,2016,Q1,Adult
114321972,11432197,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186106,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Cachexia,,2016,Q1,2,F,201507.0,20160204.0,20150828,20160212,EXP,,ES-JNJFOC-20150804226,JANSSEN,,61.0,YR,A,M,Y,65.0,KG,20160212.0,,MD,ES,ES,2016,Q1,Adult
114489513,11448951,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST WITH WATER,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Cataract,,2016,Q1,3,F,20150824.0,20160204.0,20150902,20160212,EXP,,JP-JNJFOC-20150900204,JANSSEN,,55.0,YR,A,M,Y,78.0,KG,20160212.0,,OT,JP,JP,2016,Q1,Adult
116196774,11619677,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369483,,204042.0,,,CAPSULE,,2016,Q1,Hyponatraemia,,2016,Q1,4,F,20150922.0,20160304.0,20151012,20160311,EXP,,HU-JNJFOC-20151001550,JANSSEN,,73.0,YR,E,M,Y,78.0,KG,20160311.0,,MD,HU,HU,2016,Q1,Elderly
116196774,11619677,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369483,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Hyponatraemia,,2016,Q1,4,F,20150922.0,20160304.0,20151012,20160311,EXP,,HU-JNJFOC-20151001550,JANSSEN,,73.0,YR,E,M,Y,78.0,KG,20160311.0,,MD,HU,HU,2016,Q1,Elderly
116391434,11639143,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,,,2016,Q1,Abdominal pain,,2016,Q1,4,F,20150929.0,20160216.0,20151019,20160227,EXP,,US-AUROBINDO-AUR-APL-2015-09333,AUROBINDO,,70.0,YR,,M,Y,109.7,KG,20160226.0,,OT,US,US,2016,Q1,Elderly
116391434,11639143,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,U,,,,,,,,2016,Q1,Pancreatitis acute,,2016,Q1,4,F,20150929.0,20160216.0,20151019,20160227,EXP,,US-AUROBINDO-AUR-APL-2015-09333,AUROBINDO,,70.0,YR,,M,Y,109.7,KG,20160226.0,,OT,US,US,2016,Q1,Elderly
117064593,11706459,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Cataract,,2016,Q1,3,F,20141031.0,20160204.0,20151029,20160212,EXP,,JP-JNJFOC-20151022248,JANSSEN,,69.0,YR,E,F,Y,61.0,KG,20160212.0,,OT,JP,JP,2016,Q1,Elderly
117064593,11706459,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Retinal detachment,,2016,Q1,3,F,20141031.0,20160204.0,20151029,20160212,EXP,,JP-JNJFOC-20151022248,JANSSEN,,69.0,YR,E,F,Y,61.0,KG,20160212.0,,OT,JP,JP,2016,Q1,Elderly
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Diarrhoea,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Faeces soft,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Fatigue,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Glossodynia,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Stomatitis,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
117137154,11713715,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Tongue disorder,,2016,Q1,4,F,20151030.0,20160216.0,20151109,20160229,PER,,US-BAYER-2015-463050,BAYER,,60.0,YR,A,M,Y,,,20160229.0,,PH,US,US,2016,Q1,Adult
118679073,11867907,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,,,,CAPSULE,,2016,Q1,Acidosis,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,,,,CAPSULE,,2016,Q1,Pyelonephritis acute,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,,,,CAPSULE,,2016,Q1,Septic shock,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,204042.0,300.0,MG,CAPSULE,QD,2016,Q1,Acidosis,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,204042.0,300.0,MG,CAPSULE,QD,2016,Q1,Pyelonephritis acute,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,204042.0,300.0,MG,CAPSULE,QD,2016,Q1,Septic shock,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Acidosis,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Pyelonephritis acute,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118679073,11867907,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, EDTK00Q,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Septic shock,,2016,Q1,3,F,20151113.0,20160106.0,20151224,20160112,EXP,,KR-JNJFOC-20151215648,JANSSEN,,69.0,YR,E,F,Y,60.2,KG,20160112.0,,MD,KR,KR,2016,Q1,Elderly
118850481,11885048,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q1,Gastrointestinal haemorrhage,,2016,Q1,1,I,20141006.0,20151028.0,20160104,20160104,EXP,,US-BAYER-2015-459000,BAYER,,50.0,YR,A,M,Y,,,20160104.0,,CN,US,US,2016,Q1,Adult
118851481,11885148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,,20151229.0,20160104,20160104,EXP,,US-JNJFOC-20151225912,JANSSEN,"TRACHUK P, SHIHADEH S, CHOI E. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT ON CANAGLIFLOZIN. CHEST 2015?148(4):257A.",45.0,YR,A,F,Y,,,20160104.0,,MD,US,US,2016,Q1,Adult
118851481,11885148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Off label use,,2016,Q1,1,I,,20151229.0,20160104,20160104,EXP,,US-JNJFOC-20151225912,JANSSEN,"TRACHUK P, SHIHADEH S, CHOI E. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT ON CANAGLIFLOZIN. CHEST 2015?148(4):257A.",45.0,YR,A,F,Y,,,20160104.0,,MD,US,US,2016,Q1,Adult
118851481,11885148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Product use issue,,2016,Q1,1,I,,20151229.0,20160104,20160104,EXP,,US-JNJFOC-20151225912,JANSSEN,"TRACHUK P, SHIHADEH S, CHOI E. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT ON CANAGLIFLOZIN. CHEST 2015?148(4):257A.",45.0,YR,A,F,Y,,,20160104.0,,MD,US,US,2016,Q1,Adult
118854542,11885454,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, T195186,,204042.0,,,CAPSULE,,2016,Q1,Cardio-respiratory arrest,,2016,Q1,2,F,20151220.0,20160112.0,20160104,20160114,PER,,IN-JNJFOC-20151224686,JANSSEN,,70.0,YR,E,M,Y,,,20160114.0,,MD,IN,IN,2016,Q1,Elderly
118854542,11885454,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 MG OR 300 MG,,,,N, T195186,,76479.0,,,CAPSULE,,2016,Q1,Cardio-respiratory arrest,,2016,Q1,2,F,20151220.0,20160112.0,20160104,20160114,PER,,IN-JNJFOC-20151224686,JANSSEN,,70.0,YR,E,M,Y,,,20160114.0,,MD,IN,IN,2016,Q1,Elderly
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Dizziness,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Gait disturbance,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Injection site abscess,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Injection site pain,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Injection site paraesthesia,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Injection site swelling,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
118989222,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Nausea,,2016,Q1,2,F,2015.0,20160322.0,20160108,20160330,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160330.0,,CN,US,US,2016,Q1,Young Adult
119199331,11919933,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Cardiac failure congestive,,2016,Q1,1,I,20160112.0,,20160114,20160114,DIR,,,,,64.0,YR,,M,N,96.1,KG,20160113.0,N,PH,US,,2016,Q1,Adult
119199331,11919933,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Dyspnoea,,2016,Q1,1,I,20160112.0,,20160114,20160114,DIR,,,,,64.0,YR,,M,N,96.1,KG,20160113.0,N,PH,US,,2016,Q1,Adult
119238972,11923897,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Inhibitory drug interaction,,2016,Q1,2,F,,20160224.0,20160118,20160301,EXP,,GB-JNJFOC-20160110832,JANSSEN,,57.0,YR,A,M,Y,181.0,KG,20160301.0,,MD,GB,GB,2016,Q1,Adult
119383332,11938333,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,,U,,,,100.0,MG,,,2016,Q1,Inhibitory drug interaction,,2016,Q1,2,F,,20160224.0,20160122,20160304,EXP,GB-MHRA-EYC 00133501,"GB-TARO PHARMACEUTICALS USA.,INC-2016SUN00024",TARO,,57.0,YR,,M,Y,181.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
119383332,11938333,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,,U,,,,100.0,MG,,,2016,Q1,International normalised ratio decreased,,2016,Q1,2,F,,20160224.0,20160122,20160304,EXP,GB-MHRA-EYC 00133501,"GB-TARO PHARMACEUTICALS USA.,INC-2016SUN00024",TARO,,57.0,YR,,M,Y,181.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
119709581,11970958,1,PS,CANAGLIFLOZIN 300 MG,CANAGLIFLOZIN,1,Oral,1 PILL QD ORAL,,,N,D,,,,,,,QD,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20151220.0,,20160127,20160127,DIR,,,,,51.0,YR,,F,N,96.6,KG,20160126.0,Y,,COUNTRY NOT SPECIFIED,,2016,Q1,Adult
119766991,11976699,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q1,Dry mouth,,2016,Q1,1,I,20151217.0,20160122.0,20160129,20160129,EXP,,GB-JNJFOC-20160117961,JANSSEN,,38.0,YR,A,F,Y,88.8,KG,20160129.0,,OT,GB,GB,2016,Q1,Adult
119766991,11976699,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q1,Dyskinesia,,2016,Q1,1,I,20151217.0,20160122.0,20160129,20160129,EXP,,GB-JNJFOC-20160117961,JANSSEN,,38.0,YR,A,F,Y,88.8,KG,20160129.0,,OT,GB,GB,2016,Q1,Adult
119766991,11976699,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q1,Paraesthesia,,2016,Q1,1,I,20151217.0,20160122.0,20160129,20160129,EXP,,GB-JNJFOC-20160117961,JANSSEN,,38.0,YR,A,F,Y,88.8,KG,20160129.0,,OT,GB,GB,2016,Q1,Adult
119766991,11976699,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q1,Somnolence,,2016,Q1,1,I,20151217.0,20160122.0,20160129,20160129,EXP,,GB-JNJFOC-20160117961,JANSSEN,,38.0,YR,A,F,Y,88.8,KG,20160129.0,,OT,GB,GB,2016,Q1,Adult
119988031,11998803,1,PS,CANAGLIFLOZIN 100 MG,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q1,Abdominal pain upper,,2016,Q1,1,I,20151201.0,,20160202,20160202,DIR,,,,,74.0,YR,,M,N,201.0,LBS,20160201.0,N,MD,US,,2016,Q1,Elderly
119988031,11998803,1,PS,CANAGLIFLOZIN 100 MG,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q1,Flank pain,,2016,Q1,1,I,20151201.0,,20160202,20160202,DIR,,,,,74.0,YR,,M,N,201.0,LBS,20160201.0,N,MD,US,,2016,Q1,Elderly
120010281,12001028,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED),,,,U,,,204042.0,,,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,,20160201.0,20160204,20160204,EXP,,GB-JNJFOC-20160201670,JANSSEN,,55.0,YR,A,F,Y,,,20160204.0,,MD,GB,GB,2016,Q1,Adult
120378661,12037866,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160120.0,,20160205,20160205,DIR,,,,,60.0,YR,,F,N,201.0,LBS,20160120.0,N,MD,US,,2016,Q1,Adult
120396621,12039662,1,PS,CANAGLIFLOZIN 100 MG JANSEEN PHARMACEUTICALS,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20150113.0,,20160205,20160205,DIR,,,,,57.0,YR,,F,N,55.0,KG,20160204.0,N,PH,US,,2016,Q1,Adult
120537052,12053705,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2016,Q1,Ketoacidosis,,2016,Q1,2,F,,20160208.0,20160209,20160211,EXP,,JP-009507513-1602JPN004169,MERCK,,27.0,YR,,F,Y,,,20160211.0,,CN,JP,JP,2016,Q1,Young Adult
120537052,12053705,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2016,Q1,Polyuria,,2016,Q1,2,F,,20160208.0,20160209,20160211,EXP,,JP-009507513-1602JPN004169,MERCK,,27.0,YR,,F,Y,,,20160211.0,,CN,JP,JP,2016,Q1,Young Adult
120727141,12072714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Dehydration,,2016,Q1,1,I,20160131.0,20160211.0,20160212,20160212,EXP,,GB-JNJFOC-20160210701,JANSSEN,,35.0,YR,A,M,Y,141.4,KG,20160212.0,,CN,GB,GB,2016,Q1,Adult
120727141,12072714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Gastroenteritis,,2016,Q1,1,I,20160131.0,20160211.0,20160212,20160212,EXP,,GB-JNJFOC-20160210701,JANSSEN,,35.0,YR,A,M,Y,141.4,KG,20160212.0,,CN,GB,GB,2016,Q1,Adult
120727141,12072714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Hyperglycaemia,,2016,Q1,1,I,20160131.0,20160211.0,20160212,20160212,EXP,,GB-JNJFOC-20160210701,JANSSEN,,35.0,YR,A,M,Y,141.4,KG,20160212.0,,CN,GB,GB,2016,Q1,Adult
120727141,12072714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Ketoacidosis,,2016,Q1,1,I,20160131.0,20160211.0,20160212,20160212,EXP,,GB-JNJFOC-20160210701,JANSSEN,,35.0,YR,A,M,Y,141.4,KG,20160212.0,,CN,GB,GB,2016,Q1,Adult
120844302,12084430,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q1,Cardiac disorder,,2016,Q1,2,F,20141015.0,20160310.0,20160217,20160322,EXP,,US-BAYER-2016-018885,BAYER,,58.0,YR,A,M,Y,117.0,KG,20160322.0,,CN,US,US,2016,Q1,Adult
120844302,12084430,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q1,Epistaxis,,2016,Q1,2,F,20141015.0,20160310.0,20160217,20160322,EXP,,US-BAYER-2016-018885,BAYER,,58.0,YR,A,M,Y,117.0,KG,20160322.0,,CN,US,US,2016,Q1,Adult
120844302,12084430,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q1,Internal haemorrhage,,2016,Q1,2,F,20141015.0,20160310.0,20160217,20160322,EXP,,US-BAYER-2016-018885,BAYER,,58.0,YR,A,M,Y,117.0,KG,20160322.0,,CN,US,US,2016,Q1,Adult
121094061,12109406,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q1,Ketoacidosis,,2016,Q1,1,I,20151025.0,,20160222,20160222,DIR,,,,,65.0,YR,,M,N,,,20151201.0,N,PH,US,,2016,Q1,Elderly
121094061,12109406,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q1,Metabolic acidosis,,2016,Q1,1,I,20151025.0,,20160222,20160222,DIR,,,,,65.0,YR,,M,N,,,20151201.0,N,PH,US,,2016,Q1,Elderly
121094061,12109406,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q1,Tachycardia,,2016,Q1,1,I,20151025.0,,20160222,20160222,DIR,,,,,65.0,YR,,M,N,,,20151201.0,N,PH,US,,2016,Q1,Elderly
121094061,12109406,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q1,Tachypnoea,,2016,Q1,1,I,20151025.0,,20160222,20160222,DIR,,,,,65.0,YR,,M,N,,,20151201.0,N,PH,US,,2016,Q1,Elderly
121148541,12114854,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Ketoacidosis,,2016,Q1,1,I,20160216.0,,20160224,20160224,DIR,,,,,27.0,YR,,F,N,84.0,KG,20160223.0,N,PH,US,,2016,Q1,Young Adult
121196801,12119680,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Pyrexia,,2016,Q1,1,I,,20160219.0,20160226,20160226,EXP,,GB-JNJFOC-20160218143,JANSSEN,,70.0,YR,E,F,Y,,,20160226.0,,PH,GB,GB,2016,Q1,Elderly
121309801,12130980,1,PS, CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,D,D,,,,,,,,2016,Q1,Ketoacidosis,,2016,Q1,1,I,20160226.0,,20160229,20160229,DIR,,,,,57.0,YR,,F,N,71.0,KG,20160226.0,N,PH,COUNTRY NOT SPECIFIED,,2016,Q1,Adult
121401431,12140143,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Balance disorder,,2016,Q1,1,I,20160202.0,,20160302,20160302,DIR,,,,,56.0,YR,,F,N,,,20160204.0,N,CN,US,,2016,Q1,Adult
121401431,12140143,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Burning sensation,,2016,Q1,1,I,20160202.0,,20160302,20160302,DIR,,,,,56.0,YR,,F,N,,,20160204.0,N,CN,US,,2016,Q1,Adult
121401431,12140143,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Facial pain,,2016,Q1,1,I,20160202.0,,20160302,20160302,DIR,,,,,56.0,YR,,F,N,,,20160204.0,N,CN,US,,2016,Q1,Adult
121401431,12140143,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q1,Hypoaesthesia,,2016,Q1,1,I,20160202.0,,20160302,20160302,DIR,,,,,56.0,YR,,F,N,,,20160204.0,N,CN,US,,2016,Q1,Adult
121423171,12142317,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,U,,,,100.0,MG,,QD,2016,Q1,Inhibitory drug interaction,,2016,Q1,1,I,,20160224.0,20160303,20160303,EXP,GB-MHRA-EYC 00133501,GB-TEVA-639639ACC,TEVA,,57.0,YR,,M,Y,181.0,KG,20160303.0,,MD,GB,GB,2016,Q1,Adult
121423171,12142317,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,U,,,,100.0,MG,,QD,2016,Q1,International normalised ratio decreased,,2016,Q1,1,I,,20160224.0,20160303,20160303,EXP,GB-MHRA-EYC 00133501,GB-TEVA-639639ACC,TEVA,,57.0,YR,,M,Y,181.0,KG,20160303.0,,MD,GB,GB,2016,Q1,Adult
121458391,12145839,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, FGL6 YOO,,204042.0,100.0,DF,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160218.0,20160303.0,20160304,20160304,EXP,,GB-JNJFOC-20160303503,JANSSEN,,54.0,YR,A,F,Y,70.0,KG,20160304.0,,MD,GB,GB,2016,Q1,Adult
121458411,12145841,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: ^100^,,,,N,,,204042.0,,,TABLET,,2016,Q1,Photosensitivity reaction,,2016,Q1,1,I,20160129.0,20160226.0,20160304,20160304,EXP,,GB-JNJFOC-20160226230,JANSSEN,,38.0,YR,A,M,Y,99.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121472161,12147216,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2016,Q1,Epistaxis,,2016,Q1,1,I,20150207.0,20151228.0,20160304,20160304,EXP,,US-BAYER-2016-001186,BAYER,,50.0,YR,A,F,Y,,,20160304.0,,CN,US,US,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Acute kidney injury,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Confusional state,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Malaise,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Nausea,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Somnolence,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121475421,12147542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED); ??CUMULATIVE DOSE TO FIRST RECATION 5400.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Vomiting,,2016,Q1,1,I,20160119.0,20160301.0,20160304,20160304,EXP,,GB-JNJFOC-20160300657,JANSSEN,,60.0,YR,A,M,Y,85.0,KG,20160304.0,,OT,GB,GB,2016,Q1,Adult
121630161,12163016,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,,20160301.0,20160309,20160309,EXP,,US-JNJFOC-20160308335,JANSSEN,MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015?50/9:756-60.,60.0,YR,A,M,Y,,,20160309.0,,MD,US,US,2016,Q1,Adult
121630161,12163016,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Hypercalcaemia,,2016,Q1,1,I,,20160301.0,20160309,20160309,EXP,,US-JNJFOC-20160308335,JANSSEN,MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015?50/9:756-60.,60.0,YR,A,M,Y,,,20160309.0,,MD,US,US,2016,Q1,Adult
121630161,12163016,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Hypernatraemia,,2016,Q1,1,I,,20160301.0,20160309,20160309,EXP,,US-JNJFOC-20160308335,JANSSEN,MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015?50/9:756-60.,60.0,YR,A,M,Y,,,20160309.0,,MD,US,US,2016,Q1,Adult
121630161,12163016,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Renal impairment,,2016,Q1,1,I,,20160301.0,20160309,20160309,EXP,,US-JNJFOC-20160308335,JANSSEN,MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015?50/9:756-60.,60.0,YR,A,M,Y,,,20160309.0,,MD,US,US,2016,Q1,Adult
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Chills,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Nausea,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Pallor,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Pyrexia,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Urinary tract infection,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Urosepsis,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121714931,12171493,1,PS,"CANAGLIFLOZIN 100 MG JANSSEN PHARMACEUTICALS, INC",CANAGLIFLOZIN,1,Oral,,,,D,D,,20160131,,100.0,MG,,QD,2016,Q1,Vomiting,,2016,Q1,1,I,20160106.0,,20160310,20160310,DIR,,,,,65.0,YR,,F,N,68.4,KG,20160309.0,N,PH,US,,2016,Q1,Elderly
121724581,12172458,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Acute kidney injury,,2016,Q1,1,I,20160222.0,20160303.0,20160311,20160311,EXP,,GB-JNJFOC-20160303509,JANSSEN,,37.0,YR,A,M,Y,,,20160311.0,,MD,GB,GB,2016,Q1,Adult
121724581,12172458,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q1,Influenza like illness,,2016,Q1,1,I,20160222.0,20160303.0,20160311,20160311,EXP,,GB-JNJFOC-20160303509,JANSSEN,,37.0,YR,A,M,Y,,,20160311.0,,MD,GB,GB,2016,Q1,Adult
121781711,12178171,1,PS,CANAGLIFLOZIN 300 MG,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160311.0,,20160314,20160314,DIR,,,,,44.0,YR,,F,N,95.3,KG,20160311.0,N,PH,US,,2016,Q1,Adult
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Dehydration,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Pollakiuria,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Skin disorder,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Urinary incontinence,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121782801,12178280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET,,,D,D,,,,1.0,DF,COATED TABLET,QD,2016,Q1,Urinary tract infection fungal,,2016,Q1,1,I,20160313.0,,20160314,20160314,DIR,,,,,81.0,YR,,F,N,138.0,LBS,20160313.0,N,PH,US,,2016,Q1,Elderly
121840161,12184016,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, UNKNOWN,,,100.0,MG,TABLET,QD,2016,Q1,Cellulitis,,2016,Q1,1,I,20160104.0,20160311.0,20160316,20160316,EXP,,GB-JNJFOC-20160312177,JANSSEN,,66.0,YR,E,F,Y,104.0,KG,20160316.0,,MD,GB,GB,2016,Q1,Elderly
121840161,12184016,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, UNKNOWN,,,100.0,MG,TABLET,QD,2016,Q1,Lymphangitis,,2016,Q1,1,I,20160104.0,20160311.0,20160316,20160316,EXP,,GB-JNJFOC-20160312177,JANSSEN,,66.0,YR,E,F,Y,104.0,KG,20160316.0,,MD,GB,GB,2016,Q1,Elderly
121840161,12184016,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, UNKNOWN,,204042.0,300.0,MG,TABLET,,2016,Q1,Cellulitis,,2016,Q1,1,I,20160104.0,20160311.0,20160316,20160316,EXP,,GB-JNJFOC-20160312177,JANSSEN,,66.0,YR,E,F,Y,104.0,KG,20160316.0,,MD,GB,GB,2016,Q1,Elderly
121840161,12184016,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, UNKNOWN,,204042.0,300.0,MG,TABLET,,2016,Q1,Lymphangitis,,2016,Q1,1,I,20160104.0,20160311.0,20160316,20160316,EXP,,GB-JNJFOC-20160312177,JANSSEN,,66.0,YR,E,F,Y,104.0,KG,20160316.0,,MD,GB,GB,2016,Q1,Elderly
121840171,12184017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 DOSE,,,,N,,,204042.0,,,TABLET,,2016,Q1,Acute kidney injury,,2016,Q1,1,I,20160222.0,20160304.0,20160316,20160316,EXP,,GB-JNJFOC-20160314441,JANSSEN,,36.0,YR,A,M,Y,95.0,KG,20160316.0,,OT,GB,GB,2016,Q1,Adult
121840171,12184017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 DOSE,,,,N,,,204042.0,,,TABLET,,2016,Q1,Blood electrolytes abnormal,,2016,Q1,1,I,20160222.0,20160304.0,20160316,20160316,EXP,,GB-JNJFOC-20160314441,JANSSEN,,36.0,YR,A,M,Y,95.0,KG,20160316.0,,OT,GB,GB,2016,Q1,Adult
121840171,12184017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 DOSE,,,,N,,,204042.0,,,TABLET,,2016,Q1,Blood urea abnormal,,2016,Q1,1,I,20160222.0,20160304.0,20160316,20160316,EXP,,GB-JNJFOC-20160314441,JANSSEN,,36.0,YR,A,M,Y,95.0,KG,20160316.0,,OT,GB,GB,2016,Q1,Adult
121840171,12184017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 DOSE,,,,N,,,204042.0,,,TABLET,,2016,Q1,Malaise,,2016,Q1,1,I,20160222.0,20160304.0,20160316,20160316,EXP,,GB-JNJFOC-20160314441,JANSSEN,,36.0,YR,A,M,Y,95.0,KG,20160316.0,,OT,GB,GB,2016,Q1,Adult
121907661,12190766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100??4 IN TOTAL,,,,N,,,204042.0,,,TABLET,,2016,Q1,Abdominal pain upper,,2016,Q1,1,I,20160303.0,20160315.0,20160318,20160318,EXP,,GB-JNJFOC-20160314446,JANSSEN,,57.0,YR,A,F,Y,75.0,KG,20160318.0,,MD,GB,GB,2016,Q1,Adult
121907661,12190766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100??4 IN TOTAL,,,,N,,,204042.0,,,TABLET,,2016,Q1,Nausea,,2016,Q1,1,I,20160303.0,20160315.0,20160318,20160318,EXP,,GB-JNJFOC-20160314446,JANSSEN,,57.0,YR,A,F,Y,75.0,KG,20160318.0,,MD,GB,GB,2016,Q1,Adult
121907661,12190766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100??4 IN TOTAL,,,,N,,,204042.0,,,TABLET,,2016,Q1,Vomiting,,2016,Q1,1,I,20160303.0,20160315.0,20160318,20160318,EXP,,GB-JNJFOC-20160314446,JANSSEN,,57.0,YR,A,F,Y,75.0,KG,20160318.0,,MD,GB,GB,2016,Q1,Adult
121907671,12190767,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q1,Hyperkalaemia,,2016,Q1,1,I,20160304.0,20160316.0,20160318,20160318,EXP,,GB-JNJFOC-20160315634,JANSSEN,,55.0,YR,A,F,Y,81.5,KG,20160318.0,,MD,GB,GB,2016,Q1,Adult
122073151,12207315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED) IN MORNING; CUMULATIVE DOSE TO FIRST REACTION 5200.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160211.0,20160323.0,20160324,20160324,EXP,,GB-JNJFOC-20160322029,JANSSEN,,57.0,YR,A,F,Y,,,20160324.0,,PH,GB,GB,2016,Q1,Adult
122073151,12207315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED) IN MORNING; CUMULATIVE DOSE TO FIRST REACTION 5200.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Dyspnoea,,2016,Q1,1,I,20160211.0,20160323.0,20160324,20160324,EXP,,GB-JNJFOC-20160322029,JANSSEN,,57.0,YR,A,F,Y,,,20160324.0,,PH,GB,GB,2016,Q1,Adult
122073151,12207315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED) IN MORNING; CUMULATIVE DOSE TO FIRST REACTION 5200.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Malaise,,2016,Q1,1,I,20160211.0,20160323.0,20160324,20160324,EXP,,GB-JNJFOC-20160322029,JANSSEN,,57.0,YR,A,F,Y,,,20160324.0,,PH,GB,GB,2016,Q1,Adult
122073151,12207315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED) IN MORNING; CUMULATIVE DOSE TO FIRST REACTION 5200.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Nausea,,2016,Q1,1,I,20160211.0,20160323.0,20160324,20160324,EXP,,GB-JNJFOC-20160322029,JANSSEN,,57.0,YR,A,F,Y,,,20160324.0,,PH,GB,GB,2016,Q1,Adult
122073151,12207315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100.0 (UNITS UNSPECIFIED) IN MORNING; CUMULATIVE DOSE TO FIRST REACTION 5200.0(UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q1,Respiratory acidosis,,2016,Q1,1,I,20160211.0,20160323.0,20160324,20160324,EXP,,GB-JNJFOC-20160322029,JANSSEN,,57.0,YR,A,F,Y,,,20160324.0,,PH,GB,GB,2016,Q1,Adult
122114661,12211466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 PILL QD ORAL,,,Y,D,,,,1.0,DF,,QD,2016,Q1,Diabetic ketoacidosis,,2016,Q1,1,I,20160322.0,,20160324,20160324,DIR,,,,,70.0,YR,,F,N,71.0,KG,20160323.0,N,MD,US,,2016,Q1,Elderly
122114661,12211466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 PILL QD ORAL,,,Y,D,,,,1.0,DF,,QD,2016,Q1,Metabolic acidosis,,2016,Q1,1,I,20160322.0,,20160324,20160324,DIR,,,,,70.0,YR,,F,N,71.0,KG,20160323.0,N,MD,US,,2016,Q1,Elderly
122134971,12213497,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,AS DIRECTED,,,,U,,,204042.0,,,TABLET,,2016,Q1,Chest discomfort,,2016,Q1,1,I,20160316.0,20160324.0,20160328,20160328,EXP,,GB-JNJFOC-20160323422,JANSSEN,,44.0,YR,A,M,Y,99.0,KG,20160328.0,,MD,GB,GB,2016,Q1,Adult
122134971,12213497,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,AS DIRECTED,,,,U,,,204042.0,,,TABLET,,2016,Q1,Dyspnoea,,2016,Q1,1,I,20160316.0,20160324.0,20160328,20160328,EXP,,GB-JNJFOC-20160323422,JANSSEN,,44.0,YR,A,M,Y,99.0,KG,20160328.0,,MD,GB,GB,2016,Q1,Adult
122267341,12226734,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 362952,,204042.0,,,CAPSULE,,2016,Q1,Acute coronary syndrome,,2016,Q1,1,I,20150929.0,20160128.0,20160331,20160331,EXP,,IN-JNJFOC-20160123359,JANSSEN,,75.0,YR,E,M,Y,63.0,KG,20160331.0,,MD,IN,IN,2016,Q1,Elderly
122267341,12226734,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 362952,,76479.0,100.0,MG,CAPSULE,QD,2016,Q1,Acute coronary syndrome,,2016,Q1,1,I,20150929.0,20160128.0,20160331,20160331,EXP,,IN-JNJFOC-20160123359,JANSSEN,,75.0,YR,E,M,Y,63.0,KG,20160331.0,,MD,IN,IN,2016,Q1,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Abdominal discomfort,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Bladder cancer recurrent,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Bladder catheterisation,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Bladder repair,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Chest discomfort,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Chest pain,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Cystitis,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Decreased appetite,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Diarrhoea,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Dizziness,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Dysphonia,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Dyspnoea exertional,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Faeces discoloured,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Fatigue,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Haemorrhage,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Heart rate abnormal,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Nausea,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Palpitations,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Productive cough,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Pyrexia,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Rhinorrhoea,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Urinary bladder haemorrhage,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
109750577,10975057,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Vomiting,,2016,Q2,7,F,,20160425.0,20150401,20160505,EXP,,US-ACTELION-A-NJ2015-115321,ACTELION,,70.0,YR,E,F,Y,56.24,KG,20160505.0,,OT,US,US,2016,Q2,Elderly
110678705,11067870,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, 14KG437,,,100.0,MG,CAPSULE,,2016,Q2,Dehydration,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
110678705,11067870,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, 14KG437,,,100.0,MG,CAPSULE,,2016,Q2,Hyperkalaemia,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
110678705,11067870,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, 14KG437,,,300.0,MG,CAPSULE,QD,2016,Q2,Dehydration,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
110678705,11067870,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N, 14KG437,,,300.0,MG,CAPSULE,QD,2016,Q2,Hyperkalaemia,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
110678705,11067870,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DRUG START TIME: 07:13 HOURS??DRUG END TIME: 08:00 HOURS,,,,N, 14KG437,,204042.0,300.0,MG,CAPSULE,QD,2016,Q2,Dehydration,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
110678705,11067870,3,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DRUG START TIME: 07:13 HOURS??DRUG END TIME: 08:00 HOURS,,,,N, 14KG437,,204042.0,300.0,MG,CAPSULE,QD,2016,Q2,Hyperkalaemia,,2016,Q2,5,F,20150407.0,20160617.0,20150427,20160622,EXP,,US-JNJFOC-20150414775,JANSSEN,,52.0,YR,A,M,Y,88.0,KG,20160622.0,,MD,US,US,2016,Q2,Adult
114321973,11432197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186106,,204042.0,,,CAPSULE,,2016,Q2,Cachexia,,2016,Q2,3,F,201507.0,20160609.0,20150828,20160615,EXP,,ES-JNJFOC-20150804226,JANSSEN,,61.0,YR,A,M,Y,65.0,KG,20160615.0,,MD,ES,ES,2016,Q2,Adult
114321973,11432197,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186106,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Cachexia,,2016,Q2,3,F,201507.0,20160609.0,20150828,20160615,EXP,,ES-JNJFOC-20150804226,JANSSEN,,61.0,YR,A,M,Y,65.0,KG,20160615.0,,MD,ES,ES,2016,Q2,Adult
116465892,11646589,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,TABLET,,2016,Q2,Alopecia,,2016,Q2,2,F,20150806.0,20150930.0,20151020,20160429,PER,,US-ROCHE-1624987,ROCHE,,60.0,YR,,F,Y,78.0,KG,20160430.0,,MD,US,US,2016,Q2,Adult
116465892,11646589,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,TABLET,,2016,Q2,Cough,,2016,Q2,2,F,20150806.0,20150930.0,20151020,20160429,PER,,US-ROCHE-1624987,ROCHE,,60.0,YR,,F,Y,78.0,KG,20160430.0,,MD,US,US,2016,Q2,Adult
116465892,11646589,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,TABLET,,2016,Q2,Rash,,2016,Q2,2,F,20150806.0,20150930.0,20151020,20160429,PER,,US-ROCHE-1624987,ROCHE,,60.0,YR,,F,Y,78.0,KG,20160430.0,,MD,US,US,2016,Q2,Adult
117582422,11758242,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186322,,204042.0,,,CAPSULE,,2016,Q2,Prostatitis,,2016,Q2,2,F,20151031.0,20160531.0,20151120,20160603,EXP,,TW-JNJFOC-20151103161,JANSSEN,,60.0,YR,A,M,Y,65.0,KG,20160603.0,,MD,TW,TW,2016,Q2,Adult
117582422,11758242,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B186322,,76479.0,300.0,MG,CAPSULE,QD,2016,Q2,Prostatitis,,2016,Q2,2,F,20151031.0,20160531.0,20151120,20160603,EXP,,TW-JNJFOC-20151103161,JANSSEN,,60.0,YR,A,M,Y,65.0,KG,20160603.0,,MD,TW,TW,2016,Q2,Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Arthralgia,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Dizziness,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Gait disturbance,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Injection site abscess,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Injection site pain,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Injection site paraesthesia,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Injection site swelling,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
118989223,11898922,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Nausea,,2016,Q2,3,F,2015.0,20160602.0,20160108,20160609,EXP,,US-PFIZER INC-2016002261,PFIZER,,26.0,YR,,F,Y,73.0,KG,20160609.0,,CN,US,US,2016,Q2,Young Adult
121638532,12163853,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q2,Alpha 1 foetoprotein increased,,2016,Q2,2,F,20150529.0,20160330.0,20160309,20160407,EXP,,US-BAYER-2015-295521,BAYER,,50.0,YR,A,M,Y,,,20160407.0,,MD,US,US,2016,Q2,Adult
121638532,12163853,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q2,Drug dose omission,,2016,Q2,2,F,20150529.0,20160330.0,20160309,20160407,EXP,,US-BAYER-2015-295521,BAYER,,50.0,YR,A,M,Y,,,20160407.0,,MD,US,US,2016,Q2,Adult
121638532,12163853,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q2,Drug ineffective,,2016,Q2,2,F,20150529.0,20160330.0,20160309,20160407,EXP,,US-BAYER-2015-295521,BAYER,,50.0,YR,A,M,Y,,,20160407.0,,MD,US,US,2016,Q2,Adult
121638532,12163853,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q2,Drug interaction,,2016,Q2,2,F,20150529.0,20160330.0,20160309,20160407,EXP,,US-BAYER-2015-295521,BAYER,,50.0,YR,A,M,Y,,,20160407.0,,MD,US,US,2016,Q2,Adult
121638532,12163853,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2016,Q2,Paraesthesia,,2016,Q2,2,F,20150529.0,20160330.0,20160309,20160407,EXP,,US-BAYER-2015-295521,BAYER,,50.0,YR,A,M,Y,,,20160407.0,,MD,US,US,2016,Q2,Adult
122267342,12226734,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 362952,,204042.0,,,CAPSULE,,2016,Q2,Acute coronary syndrome,,2016,Q2,2,F,20150929.0,20160601.0,20160331,20160607,EXP,,IN-JNJFOC-20160123359,JANSSEN,,75.0,YR,E,M,Y,63.0,KG,20160607.0,,MD,IN,IN,2016,Q2,Elderly
122267342,12226734,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 362952,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Acute coronary syndrome,,2016,Q2,2,F,20150929.0,20160601.0,20160331,20160607,EXP,,IN-JNJFOC-20160123359,JANSSEN,,75.0,YR,E,M,Y,63.0,KG,20160607.0,,MD,IN,IN,2016,Q2,Elderly
122322632,12232263,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,2,F,20160317.0,20160413.0,20160401,20160415,EXP,,GB-JNJFOC-20160328077,JANSSEN,,60.0,YR,A,F,Y,80.0,KG,20160415.0,,PH,GB,GB,2016,Q2,Adult
122322632,12232263,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,DF,TABLET,,2016,Q2,Treatment noncompliance,,2016,Q2,2,F,20160317.0,20160413.0,20160401,20160415,EXP,,GB-JNJFOC-20160328077,JANSSEN,,60.0,YR,A,F,Y,80.0,KG,20160415.0,,PH,GB,GB,2016,Q2,Adult
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Alopecia,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Blindness unilateral,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Blister,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Candida infection,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Cellulitis,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Malaise,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Peripheral swelling,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122723461,12272346,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Rash pruritic,,2016,Q2,1,I,20160304.0,20160413.0,20160415,20160415,EXP,,GB-JNJFOC-20160412786,JANSSEN,,74.0,YR,E,F,Y,80.73,KG,20160415.0,,CN,GB,GB,2016,Q2,Elderly
122961651,12296165,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,,,,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160120.0,20160420.0,20160422,20160422,EXP,,US-JNJFOC-20160420715,JANSSEN,,60.0,YR,A,F,Y,91.17,KG,20160422.0,,MD,US,US,2016,Q2,Adult
122961651,12296165,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160120.0,20160420.0,20160422,20160422,EXP,,US-JNJFOC-20160420715,JANSSEN,,60.0,YR,A,F,Y,91.17,KG,20160422.0,,MD,US,US,2016,Q2,Adult
123131733,12313173,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4367909,,204042.0,,,CAPSULE,,2016,Q2,Diabetic foot infection,,2016,Q2,3,F,20141224.0,20160505.0,20160428,20160511,EXP,,NZ-JNJFOC-20150209744,JANSSEN,,71.0,YR,E,M,Y,86.0,KG,20160511.0,,MD,NZ,NZ,2016,Q2,Elderly
123131733,12313173,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4367909,,204042.0,,,CAPSULE,,2016,Q2,Localised infection,,2016,Q2,3,F,20141224.0,20160505.0,20160428,20160511,EXP,,NZ-JNJFOC-20150209744,JANSSEN,,71.0,YR,E,M,Y,86.0,KG,20160511.0,,MD,NZ,NZ,2016,Q2,Elderly
123131733,12313173,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4367909,,76479.0,300.0,MG,CAPSULE,QD,2016,Q2,Diabetic foot infection,,2016,Q2,3,F,20141224.0,20160505.0,20160428,20160511,EXP,,NZ-JNJFOC-20150209744,JANSSEN,,71.0,YR,E,M,Y,86.0,KG,20160511.0,,MD,NZ,NZ,2016,Q2,Elderly
123131733,12313173,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4367909,,76479.0,300.0,MG,CAPSULE,QD,2016,Q2,Localised infection,,2016,Q2,3,F,20141224.0,20160505.0,20160428,20160511,EXP,,NZ-JNJFOC-20150209744,JANSSEN,,71.0,YR,E,M,Y,86.0,KG,20160511.0,,MD,NZ,NZ,2016,Q2,Elderly
123271511,12327151,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Rash erythematous,,2016,Q2,1,I,,20160427.0,20160503,20160503,EXP,,GB-JNJFOC-20160425015,JANSSEN,,65.0,YR,A,M,Y,102.0,KG,20160503.0,,MD,GB,GB,2016,Q2,Elderly
123271511,12327151,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Rash maculo-papular,,2016,Q2,1,I,,20160427.0,20160503,20160503,EXP,,GB-JNJFOC-20160425015,JANSSEN,,65.0,YR,A,M,Y,102.0,KG,20160503.0,,MD,GB,GB,2016,Q2,Elderly
123271511,12327151,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Skin exfoliation,,2016,Q2,1,I,,20160427.0,20160503,20160503,EXP,,GB-JNJFOC-20160425015,JANSSEN,,65.0,YR,A,M,Y,102.0,KG,20160503.0,,MD,GB,GB,2016,Q2,Elderly
123405761,12340576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,,,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160402.0,20160505.0,20160506,20160506,EXP,,GB-JNJFOC-20160505287,JANSSEN,,65.0,YR,A,M,Y,88.0,KG,20160506.0,,OT,GB,GB,2016,Q2,Elderly
123426811,12342681,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Acute kidney injury,,2016,Q2,1,I,,20160503.0,20160506,20160506,EXP,,US-JNJFOC-20160505321,JANSSEN,"TAHIR H, WANI A, DARUWALLA V, DABOUL N, SAGI J. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT. JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD 2015;27/4:923-4.",29.0,YR,A,M,Y,,,20160506.0,,OT,US,US,2016,Q2,Young Adult
123426811,12342681,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,,20160503.0,20160506,20160506,EXP,,US-JNJFOC-20160505321,JANSSEN,"TAHIR H, WANI A, DARUWALLA V, DABOUL N, SAGI J. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT. JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD 2015;27/4:923-4.",29.0,YR,A,M,Y,,,20160506.0,,OT,US,US,2016,Q2,Young Adult
123426811,12342681,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Off label use,,2016,Q2,1,I,,20160503.0,20160506,20160506,EXP,,US-JNJFOC-20160505321,JANSSEN,"TAHIR H, WANI A, DARUWALLA V, DABOUL N, SAGI J. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT. JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD 2015;27/4:923-4.",29.0,YR,A,M,Y,,,20160506.0,,OT,US,US,2016,Q2,Young Adult
123426811,12342681,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Product use issue,,2016,Q2,1,I,,20160503.0,20160506,20160506,EXP,,US-JNJFOC-20160505321,JANSSEN,"TAHIR H, WANI A, DARUWALLA V, DABOUL N, SAGI J. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT. JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD 2015;27/4:923-4.",29.0,YR,A,M,Y,,,20160506.0,,OT,US,US,2016,Q2,Young Adult
123638681,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Drug ineffective,,2016,Q2,1,I,20150421.0,20150515.0,20160512,20160512,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20160512.0,,PH,US,US,2016,Q2,Adult
123638681,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Off label use,,2016,Q2,1,I,20150421.0,20150515.0,20160512,20160512,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20160512.0,,PH,US,US,2016,Q2,Adult
123638681,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q2,Pruritus,,2016,Q2,1,I,20150421.0,20150515.0,20160512,20160512,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20160512.0,,PH,US,US,2016,Q2,Adult
123684021,12368402,2,C,CANAGLIFLOZIN W/METFORMIN HYDROCHLORIDE,,2,,"UNK, [CANAGLIFLOZIN 150 MG]/[ METFORMIN HYDROCHLORIDE 1000 MG]",,,,,,,,,,,,2016,Q2,Condition aggravated,,2016,Q2,1,I,,20160420.0,20160513,20160513,PER,,PR-PFIZER INC-2016227660,PFIZER,,37.0,YR,,F,Y,64.0,KG,20160513.0,,CN,PR,PR,2016,Q2,Adult
123684021,12368402,2,C,CANAGLIFLOZIN W/METFORMIN HYDROCHLORIDE,,2,,"UNK, [CANAGLIFLOZIN 150 MG]/[ METFORMIN HYDROCHLORIDE 1000 MG]",,,,,,,,,,,,2016,Q2,Pain,,2016,Q2,1,I,,20160420.0,20160513,20160513,PER,,PR-PFIZER INC-2016227660,PFIZER,,37.0,YR,,F,Y,64.0,KG,20160513.0,,CN,PR,PR,2016,Q2,Adult
123733282,12373328,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,2,F,20151108.0,20160513.0,20160516,20160518,EXP,,GB-JNJFOC-20160513666,JANSSEN,,42.0,YR,A,F,Y,,,20160518.0,,MD,GB,GB,2016,Q2,Adult
123733282,12373328,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q2,Vomiting,,2016,Q2,2,F,20151108.0,20160513.0,20160516,20160518,EXP,,GB-JNJFOC-20160513666,JANSSEN,,42.0,YR,A,F,Y,,,20160518.0,,MD,GB,GB,2016,Q2,Adult
123814921,12381492,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 (UNITS UNSPECIFIED),,,,N,,,204042.0,,,TABLET,,2016,Q2,Skin ulcer,,2016,Q2,1,I,20160317.0,20160516.0,20160518,20160518,EXP,,GB-JNJFOC-20160514868,JANSSEN,,61.0,YR,A,M,Y,111.0,KG,20160518.0,,OT,GB,GB,2016,Q2,Adult
123893501,12389350,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B206492,,204042.0,100.0,MG,CAPSULE,QD,2016,Q2,Cardiac failure,,2016,Q2,1,I,20160426.0,20160510.0,20160520,20160520,EXP,,MY-JNJFOC-20160511836,JANSSEN,,46.0,YR,A,M,Y,,,20160520.0,,OT,MY,MY,2016,Q2,Adult
123893501,12389350,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B206492,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Cardiac failure,,2016,Q2,1,I,20160426.0,20160510.0,20160520,20160520,EXP,,MY-JNJFOC-20160511836,JANSSEN,,46.0,YR,A,M,Y,,,20160520.0,,OT,MY,MY,2016,Q2,Adult
123907463,12390746,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,,100.0,MG,CAPSULE,QD,2016,Q2,Amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,,100.0,MG,CAPSULE,QD,2016,Q2,Extremity necrosis,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,,100.0,MG,CAPSULE,QD,2016,Q2,Foot amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,204042.0,100.0,MG,CAPSULE,QD,2016,Q2,Amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,204042.0,100.0,MG,CAPSULE,QD,2016,Q2,Extremity necrosis,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,204042.0,100.0,MG,CAPSULE,QD,2016,Q2,Foot amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Extremity necrosis,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123907463,12390746,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370381,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Foot amputation,,2016,Q2,3,F,201602.0,20160622.0,20160520,20160630,EXP,,BR-JNJFOC-20160322860,JANSSEN,,67.0,YR,E,M,Y,67.7,KG,20160630.0,,MD,BR,BR,2016,Q2,Elderly
123984131,12398413,1,PS,"CANAGLIFLOZIN, 100MG",CANAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160522.0,,20160523,20160523,DIR,,,,,52.0,YR,,M,N,84.0,KG,20160523.0,N,MD,COUNTRY NOT SPECIFIED,,2016,Q2,Adult
124013152,12401315,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,Y,,,204042.0,100.0,MG,TABLET,QD,2016,Q2,Liver disorder,Liver disorder,2016,Q2,2,F,20160507.0,20160615.0,20160525,20160627,EXP,,JP-JNJFOC-20160521963,JANSSEN,,86.0,YR,E,F,Y,,,20160627.0,,OT,JP,JP,2016,Q2,Elderly
124237541,12423754,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160517.0,,20160531,20160531,DIR,,,,,58.0,YR,,M,N,94.0,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237541,12423754,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Dizziness,,2016,Q2,1,I,20160517.0,,20160531,20160531,DIR,,,,,58.0,YR,,M,N,94.0,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237541,12423754,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Headache,,2016,Q2,1,I,20160517.0,,20160531,20160531,DIR,,,,,58.0,YR,,M,N,94.0,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237541,12423754,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Nausea,,2016,Q2,1,I,20160517.0,,20160531,20160531,DIR,,,,,58.0,YR,,M,N,94.0,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237721,12423772,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Abdominal pain,,2016,Q2,1,I,20160408.0,,20160531,20160531,DIR,,,,,40.0,YR,,M,N,62.8,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237721,12423772,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160408.0,,20160531,20160531,DIR,,,,,40.0,YR,,M,N,62.8,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124237721,12423772,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q2,Nausea,,2016,Q2,1,I,20160408.0,,20160531,20160531,DIR,,,,,40.0,YR,,M,N,62.8,KG,20160527.0,N,PH,US,,2016,Q2,Adult
124250491,12425049,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Neutropenia,,2016,Q2,1,I,20160509.0,20160525.0,20160601,20160601,EXP,GB-MHRA-EYC 00139943,GB-DRREDDYS-GER/UKI/16/0080168,DR REDDYS,,65.0,YR,,M,Y,80.0,KG,20160601.0,,PH,GB,GB,2016,Q2,Elderly
124300901,12430090,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q2,Neutropenia,,2016,Q2,1,I,20160509.0,20160525.0,20160602,20160602,EXP,,GB-BAUSCH-BL-2016-012812,BAUSCH AND LOMB,,65.0,YR,,M,Y,,,20160602.0,,PH,GB,GB,2016,Q2,Elderly
124404571,12440457,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q2,Neutropenia,,2016,Q2,1,I,20160509.0,20160525.0,20160606,20160606,EXP,GB-MHRA-EYC 00139943,PHHY2016GB072737,SANDOZ,,65.0,YR,,M,Y,80.0,KG,20160606.0,,OT,GB,GB,2016,Q2,Elderly
124426691,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q2,Asthma,,2016,Q2,1,I,20160205.0,20160229.0,20160607,20160607,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20160607.0,,OT,CA,CA,2016,Q2,Young Adult
124426691,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q2,Photodermatosis,,2016,Q2,1,I,20160205.0,20160229.0,20160607,20160607,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20160607.0,,OT,CA,CA,2016,Q2,Young Adult
124426691,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q2,Vulvovaginal candidiasis,,2016,Q2,1,I,20160205.0,20160229.0,20160607,20160607,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20160607.0,,OT,CA,CA,2016,Q2,Young Adult
124435131,12443513,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2016,Q2,Neutropenia,,2016,Q2,1,I,20160509.0,20160525.0,20160607,20160607,EXP,GB-MHRA-EYC 00139943,GB-BAYER-2016-100620,BAYER,,65.0,YR,E,M,Y,80.0,KG,20160607.0,,PH,GB,GB,2016,Q2,Elderly
124483481,12448348,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Peripheral ischaemia,,2016,Q2,1,I,,20160606.0,20160608,20160608,EXP,,GB-JNJFOC-20160605025,JANSSEN,,49.0,YR,A,F,Y,104.0,KG,20160608.0,,PH,GB,GB,2016,Q2,Adult
124483481,12448348,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Skin ulcer,,2016,Q2,1,I,,20160606.0,20160608,20160608,EXP,,GB-JNJFOC-20160605025,JANSSEN,,49.0,YR,A,F,Y,104.0,KG,20160608.0,,PH,GB,GB,2016,Q2,Adult
124483481,12448348,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Vascular graft occlusion,,2016,Q2,1,I,,20160606.0,20160608,20160608,EXP,,GB-JNJFOC-20160605025,JANSSEN,,49.0,YR,A,F,Y,104.0,KG,20160608.0,,PH,GB,GB,2016,Q2,Adult
124505693,12450569,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Anaemia,,2016,Q2,3,F,20160601.0,20160603.0,20160609,20160621,EXP,,FR-JNJFOC-20160601497,JANSSEN,,66.0,YR,E,M,Y,107.0,KG,20160615.0,,MD,FR,FR,2016,Q2,Elderly
124505693,12450569,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,76479.0,300.0,MG,CAPSULE,QD,2016,Q2,Anaemia,,2016,Q2,3,F,20160601.0,20160603.0,20160609,20160621,EXP,,FR-JNJFOC-20160601497,JANSSEN,,66.0,YR,E,M,Y,107.0,KG,20160615.0,,MD,FR,FR,2016,Q2,Elderly
124628171,12462817,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q2,Ketoacidosis,,2016,Q2,1,I,20151025.0,20160420.0,20160614,20160614,PER,,US-JNJFOC-20160420736,JANSSEN,,65.0,YR,A,M,Y,,,20160614.0,,PH,US,US,2016,Q2,Elderly
124692452,12469245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Amputation,,2016,Q2,2,F,20160331.0,20160624.0,20160615,20160630,EXP,,ES-JNJFOC-20160607469,JANSSEN,,61.0,YR,A,M,Y,,,20160630.0,,MD,ES,ES,2016,Q2,Adult
124692452,12469245,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,CAPSULE,,2016,Q2,Peripheral ischaemia,,2016,Q2,2,F,20160331.0,20160624.0,20160615,20160630,EXP,,ES-JNJFOC-20160607469,JANSSEN,,61.0,YR,A,M,Y,,,20160630.0,,MD,ES,ES,2016,Q2,Adult
124692452,12469245,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 OR 300 MG,,,,N,,,76479.0,,,CAPSULE,,2016,Q2,Amputation,,2016,Q2,2,F,20160331.0,20160624.0,20160615,20160630,EXP,,ES-JNJFOC-20160607469,JANSSEN,,61.0,YR,A,M,Y,,,20160630.0,,MD,ES,ES,2016,Q2,Adult
124692452,12469245,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 OR 300 MG,,,,N,,,76479.0,,,CAPSULE,,2016,Q2,Peripheral ischaemia,,2016,Q2,2,F,20160331.0,20160624.0,20160615,20160630,EXP,,ES-JNJFOC-20160607469,JANSSEN,,61.0,YR,A,M,Y,,,20160630.0,,MD,ES,ES,2016,Q2,Adult
124753411,12475341,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Pain in extremity,,2016,Q2,1,I,,20160615.0,20160617,20160617,EXP,,GB-JNJFOC-20160613497,JANSSEN,,67.0,YR,E,F,Y,,,20160617.0,,MD,GB,GB,2016,Q2,Elderly
124753411,12475341,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Peripheral ischaemia,,2016,Q2,1,I,,20160615.0,20160617,20160617,EXP,,GB-JNJFOC-20160613497,JANSSEN,,67.0,YR,E,F,Y,,,20160617.0,,MD,GB,GB,2016,Q2,Elderly
124753411,12475341,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Peripheral vascular disorder,,2016,Q2,1,I,,20160615.0,20160617,20160617,EXP,,GB-JNJFOC-20160613497,JANSSEN,,67.0,YR,E,F,Y,,,20160617.0,,MD,GB,GB,2016,Q2,Elderly
124842631,12484263,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q2,Gastrointestinal haemorrhage,,2016,Q2,1,I,2015.0,20160408.0,20160621,20160621,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160621.0,,CN,US,US,2016,Q2,Adult
124842631,12484263,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q2,Internal haemorrhage,,2016,Q2,1,I,2015.0,20160408.0,20160621,20160621,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160621.0,,CN,US,US,2016,Q2,Adult
124842631,12484263,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q2,Iron deficiency anaemia,,2016,Q2,1,I,2015.0,20160408.0,20160621,20160621,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160621.0,,CN,US,US,2016,Q2,Adult
124842631,12484263,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q2,Rectal haemorrhage,,2016,Q2,1,I,2015.0,20160408.0,20160621,20160621,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160621.0,,CN,US,US,2016,Q2,Adult
124842631,12484263,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q2,Rectal neoplasm,,2016,Q2,1,I,2015.0,20160408.0,20160621,20160621,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160621.0,,CN,US,US,2016,Q2,Adult
124894131,12489413,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B206493,,204042.0,,,CAPSULE,,2016,Q2,Peripheral vascular disorder,,2016,Q2,1,I,20160524.0,20160614.0,20160622,20160622,EXP,,MY-JNJFOC-20160615994,JANSSEN,,79.0,YR,E,F,Y,,,20160622.0,,MD,MY,MY,2016,Q2,Elderly
124894131,12489413,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, B206493,,76479.0,100.0,MG,CAPSULE,QD,2016,Q2,Peripheral vascular disorder,,2016,Q2,1,I,20160524.0,20160614.0,20160622,20160622,EXP,,MY-JNJFOC-20160615994,JANSSEN,,79.0,YR,E,F,Y,,,20160622.0,,MD,MY,MY,2016,Q2,Elderly
124913451,12491345,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q2,Abdominal pain,,2016,Q2,1,I,20160218.0,,20160622,20160622,DIR,,,,,54.0,YR,,F,N,66.7,KG,20160621.0,N,PH,US,,2016,Q2,Adult
124913451,12491345,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q2,Burning sensation,,2016,Q2,1,I,20160218.0,,20160622,20160622,DIR,,,,,54.0,YR,,F,N,66.7,KG,20160621.0,N,PH,US,,2016,Q2,Adult
124913451,12491345,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,20160218.0,,20160622,20160622,DIR,,,,,54.0,YR,,F,N,66.7,KG,20160621.0,N,PH,US,,2016,Q2,Adult
124913451,12491345,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q2,Nausea,,2016,Q2,1,I,20160218.0,,20160622,20160622,DIR,,,,,54.0,YR,,F,N,66.7,KG,20160621.0,N,PH,US,,2016,Q2,Adult
124913451,12491345,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q2,Vomiting,,2016,Q2,1,I,20160218.0,,20160622,20160622,DIR,,,,,54.0,YR,,F,N,66.7,KG,20160621.0,N,PH,US,,2016,Q2,Adult
124918471,12491847,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, UNSURE,,204042.0,,,TABLET,,2016,Q2,Diabetes mellitus inadequate control,,2016,Q2,1,I,20151202.0,20160615.0,20160623,20160623,EXP,,GB-JNJFOC-20160613467,JANSSEN,,29.0,YR,A,F,Y,89.0,KG,20160623.0,,MD,GB,GB,2016,Q2,Young Adult
124918471,12491847,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, UNSURE,,204042.0,,,TABLET,,2016,Q2,Exposure during pregnancy,,2016,Q2,1,I,20151202.0,20160615.0,20160623,20160623,EXP,,GB-JNJFOC-20160613467,JANSSEN,,29.0,YR,A,F,Y,89.0,KG,20160623.0,,MD,GB,GB,2016,Q2,Young Adult
124974481,12497448,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE =100,,,,N,,,204042.0,,,TABLET,,2016,Q2,Diabetic ketoacidosis,,2016,Q2,1,I,2016.0,20160623.0,20160624,20160624,EXP,,GB-JNJFOC-20160622038,JANSSEN,,34.0,YR,A,M,Y,,,20160624.0,,OT,GB,GB,2016,Q2,Young Adult
125038591,12503859,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q2,Acute kidney injury,,2016,Q2,1,I,20160624.0,,20160627,20160627,DIR,,,,,55.0,YR,,M,N,106.0,KG,20160624.0,N,PH,COUNTRY NOT SPECIFIED,,2016,Q2,Adult
125075081,12507508,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2016,Q2,Blood glucose increased,,2016,Q2,1,I,20160624.0,,20160628,20160628,DIR,,,,,41.0,YR,,M,N,84.6,KG,20160627.0,N,PH,US,,2016,Q2,Adult
125075081,12507508,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2016,Q2,Feeling abnormal,,2016,Q2,1,I,20160624.0,,20160628,20160628,DIR,,,,,41.0,YR,,M,N,84.6,KG,20160627.0,N,PH,US,,2016,Q2,Adult
125075081,12507508,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2016,Q2,Vomiting,,2016,Q2,1,I,20160624.0,,20160628,20160628,DIR,,,,,41.0,YR,,M,N,84.6,KG,20160627.0,N,PH,US,,2016,Q2,Adult
125084051,12508405,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q2,Ketoacidosis,,2016,Q2,1,I,20160612.0,20160627.0,20160629,20160629,EXP,,GB-JNJFOC-20160624496,JANSSEN,,34.0,YR,A,M,Y,114.0,KG,20160629.0,,MD,GB,GB,2016,Q2,Young Adult
125101511,12510151,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,,,TABLET,,2016,Q2,Cerebral infarction,,2016,Q2,1,I,20160601.0,20160621.0,20160629,20160629,EXP,,JP-JNJFOC-20160623776,JANSSEN,,76.0,YR,E,M,Y,,,20160629.0,,MD,JP,JP,2016,Q2,Elderly
125179831,12517983,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,,,,,100.0,MG,,,2016,Q2,Skin discolouration,,2016,Q2,1,I,,20160609.0,20160630,20160630,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-047256,BRISTOL MYERS SQUIBB,,57.0,YR,,M,Y,,,20160624.0,,CN,GB,GB,2016,Q2,Adult
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Anaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Cough,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Dehydration,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Hypoglycaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Hyponatraemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Hypovolaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Liver function test increased,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Liver injury,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Pyrexia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Anaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Cough,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Dehydration,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Hypoglycaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Hyponatraemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Hypovolaemia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Liver function test increased,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Liver injury,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
106783863,10678386,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,76479.0,100.0,MG,CAPSULE,,2016,Q3,Pyrexia,,2016,Q3,3,F,20141210.0,20160804.0,20141229,20160805,EXP,,US-JNJFOC-20141212397,JANSSEN,,73.0,YR,E,M,Y,93.2,KG,20160805.0,,MD,US,US,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Acidosis,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Dehydration,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Diarrhoea,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Gastroenteritis,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Hyperglycaemia,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
108726692,10872669,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Vomiting,,2016,Q3,2,F,,20160825.0,20150227,20160825,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010812,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20160825.0,,CN,DE,JP,2016,Q3,Elderly
111595154,11159515,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,204042.0,,,CAPSULE,,2016,Q3,Penile abscess,,2016,Q3,4,F,20150421.0,20160707.0,20150603,20160718,EXP,,ES-JNJFOC-20150513880,JANSSEN,,57.0,YR,A,M,Y,,,20160718.0,,MD,ES,ES,2016,Q3,Adult
111595154,11159515,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,204042.0,,,CAPSULE,,2016,Q3,Penile prosthesis insertion,,2016,Q3,4,F,20150421.0,20160707.0,20150603,20160718,EXP,,ES-JNJFOC-20150513880,JANSSEN,,57.0,YR,A,M,Y,,,20160718.0,,MD,ES,ES,2016,Q3,Adult
111595154,11159515,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,76479.0,300.0,MG,CAPSULE,,2016,Q3,Penile abscess,,2016,Q3,4,F,20150421.0,20160707.0,20150603,20160718,EXP,,ES-JNJFOC-20150513880,JANSSEN,,57.0,YR,A,M,Y,,,20160718.0,,MD,ES,ES,2016,Q3,Adult
111595154,11159515,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,76479.0,300.0,MG,CAPSULE,,2016,Q3,Penile prosthesis insertion,,2016,Q3,4,F,20150421.0,20160707.0,20150603,20160718,EXP,,ES-JNJFOC-20150513880,JANSSEN,,57.0,YR,A,M,Y,,,20160718.0,,MD,ES,ES,2016,Q3,Adult
112274869,11227486,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST WITH WATER,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Cerebral infarction,,2016,Q3,9,F,20150617.0,20160324.0,20150630,20160822,EXP,,JP-JNJFOC-20150620341,JANSSEN,,58.0,YR,A,M,Y,79.0,KG,20160822.0,,OT,JP,JP,2016,Q3,Adult
113497842,11349784,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,2,F,,20160719.0,20150807,20160727,EXP,,US-JNJFOC-20150722668,JANSSEN,"KAUR A, MANCANO M. SEVERE HYPERCALCEMIA AND HYPERNATREMIA IN A PATIENT TREATED WITH CANAGLIFLOZIN. ENDOCRINOLOGY, DIABETES AND METABOLISM CASE REPORTS JUL-2015. MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015;50/9:756-60.",60.0,YR,A,M,Y,,,20160727.0,,MD,US,US,2016,Q3,Adult
113497842,11349784,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Hypercalcaemia,,2016,Q3,2,F,,20160719.0,20150807,20160727,EXP,,US-JNJFOC-20150722668,JANSSEN,"KAUR A, MANCANO M. SEVERE HYPERCALCEMIA AND HYPERNATREMIA IN A PATIENT TREATED WITH CANAGLIFLOZIN. ENDOCRINOLOGY, DIABETES AND METABOLISM CASE REPORTS JUL-2015. MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015;50/9:756-60.",60.0,YR,A,M,Y,,,20160727.0,,MD,US,US,2016,Q3,Adult
113497842,11349784,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Hypernatraemia,,2016,Q3,2,F,,20160719.0,20150807,20160727,EXP,,US-JNJFOC-20150722668,JANSSEN,"KAUR A, MANCANO M. SEVERE HYPERCALCEMIA AND HYPERNATREMIA IN A PATIENT TREATED WITH CANAGLIFLOZIN. ENDOCRINOLOGY, DIABETES AND METABOLISM CASE REPORTS JUL-2015. MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015;50/9:756-60.",60.0,YR,A,M,Y,,,20160727.0,,MD,US,US,2016,Q3,Adult
113497842,11349784,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Renal impairment,,2016,Q3,2,F,,20160719.0,20150807,20160727,EXP,,US-JNJFOC-20150722668,JANSSEN,"KAUR A, MANCANO M. SEVERE HYPERCALCEMIA AND HYPERNATREMIA IN A PATIENT TREATED WITH CANAGLIFLOZIN. ENDOCRINOLOGY, DIABETES AND METABOLISM CASE REPORTS JUL-2015. MANCANO M. CANAGLIFLOZIN-ASSOCIATED SEVERE HYPERCALCEMIA AND HYPERNATREMIA. HOSPITAL PHARMACY 2015;50/9:756-60.",60.0,YR,A,M,Y,,,20160727.0,,MD,US,US,2016,Q3,Adult
1170032610,11700326,1,PS,CANAGLIFLOZIN 10% MONOHYDRATE/90% HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,,,,,N, FGTK000,,204042.0,300.0,MG,TABLET,,2016,Q3,Ischaemic cerebral infarction,,2016,Q3,10,F,20151027.0,20160624.0,20151105,20160706,EXP,,NL-JNJFOC-20151021608,JANSSEN,,46.0,YR,A,F,Y,65.0,KG,20160706.0,,MD,NL,BE,2016,Q3,Adult
1170032610,11700326,1,PS,CANAGLIFLOZIN 10% MONOHYDRATE/90% HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,,,,,N, FGTK000,,204042.0,300.0,MG,TABLET,,2016,Q3,Malaise,,2016,Q3,10,F,20151027.0,20160624.0,20151105,20160706,EXP,,NL-JNJFOC-20151021608,JANSSEN,,46.0,YR,A,F,Y,65.0,KG,20160706.0,,MD,NL,BE,2016,Q3,Adult
123893502,12389350,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B206492,,204042.0,100.0,MG,CAPSULE,QD,2016,Q3,Cardiac failure,,2016,Q3,2,F,20160426.0,20160824.0,20160520,20160831,EXP,,MY-JNJFOC-20160511836,JANSSEN,,46.0,YR,A,M,Y,,,20160831.0,,OT,MY,MY,2016,Q3,Adult
123893502,12389350,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B206492,,76479.0,100.0,MG,CAPSULE,QD,2016,Q3,Cardiac failure,,2016,Q3,2,F,20160426.0,20160824.0,20160520,20160831,EXP,,MY-JNJFOC-20160511836,JANSSEN,,46.0,YR,A,M,Y,,,20160831.0,,OT,MY,MY,2016,Q3,Adult
124117782,12411778,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,CUMULATIVE DOSE TO FIRST REACTION: 100 (UNITS UNSPECIFIED); ??DOSE: 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Dyspnoea,,2016,Q3,2,F,20160226.0,20160722.0,20160527,20160728,EXP,,GB-JNJFOC-20160525776,JANSSEN,,63.0,YR,A,M,Y,113.0,KG,20160728.0,,OT,GB,GB,2016,Q3,Adult
124842633,12484263,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q3,Gastrointestinal haemorrhage,,2016,Q3,3,F,2015.0,20160803.0,20160621,20160825,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160825.0,,CN,US,US,2016,Q3,Adult
124842633,12484263,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q3,Internal haemorrhage,,2016,Q3,3,F,2015.0,20160803.0,20160621,20160825,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160825.0,,CN,US,US,2016,Q3,Adult
124842633,12484263,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q3,Iron deficiency anaemia,,2016,Q3,3,F,2015.0,20160803.0,20160621,20160825,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160825.0,,CN,US,US,2016,Q3,Adult
124842633,12484263,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q3,Rectal haemorrhage,,2016,Q3,3,F,2015.0,20160803.0,20160621,20160825,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160825.0,,CN,US,US,2016,Q3,Adult
124842633,12484263,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,TABLET,QD,2016,Q3,Rectal neoplasm,,2016,Q3,3,F,2015.0,20160803.0,20160621,20160825,EXP,,US-BAYER-2016-072719,BAYER,,59.0,YR,A,M,Y,,,20160825.0,,CN,US,US,2016,Q3,Adult
125300191,12530019,1,PS,"CANAGLIFLOZIN, 300 MG",CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q3,Acidosis,,2016,Q3,1,I,20160622.0,,20160705,20160705,DIR,,,,,61.0,YR,,F,N,93.0,KG,20160701.0,N,PH,US,,2016,Q3,Adult
125300191,12530019,1,PS,"CANAGLIFLOZIN, 300 MG",CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160622.0,,20160705,20160705,DIR,,,,,61.0,YR,,F,N,93.0,KG,20160701.0,N,PH,US,,2016,Q3,Adult
125300191,12530019,1,PS,"CANAGLIFLOZIN, 300 MG",CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q3,Fall,,2016,Q3,1,I,20160622.0,,20160705,20160705,DIR,,,,,61.0,YR,,F,N,93.0,KG,20160701.0,N,PH,US,,2016,Q3,Adult
125300191,12530019,1,PS,"CANAGLIFLOZIN, 300 MG",CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q3,Humerus fracture,,2016,Q3,1,I,20160622.0,,20160705,20160705,DIR,,,,,61.0,YR,,F,N,93.0,KG,20160701.0,N,PH,US,,2016,Q3,Adult
125300191,12530019,1,PS,"CANAGLIFLOZIN, 300 MG",CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q3,Nausea,,2016,Q3,1,I,20160622.0,,20160705,20160705,DIR,,,,,61.0,YR,,F,N,93.0,KG,20160701.0,N,PH,US,,2016,Q3,Adult
125370981,12537098,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q3,Ataxia,,2016,Q3,1,I,20160413.0,20160701.0,20160707,20160707,EXP,,GB-JNJFOC-20160701785,JANSSEN,,54.0,YR,A,M,Y,140.0,KG,20160707.0,,MD,GB,GB,2016,Q3,Adult
125370981,12537098,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q3,Demyelination,,2016,Q3,1,I,20160413.0,20160701.0,20160707,20160707,EXP,,GB-JNJFOC-20160701785,JANSSEN,,54.0,YR,A,M,Y,140.0,KG,20160707.0,,MD,GB,GB,2016,Q3,Adult
125370981,12537098,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q3,Multiple sclerosis,,2016,Q3,1,I,20160413.0,20160701.0,20160707,20160707,EXP,,GB-JNJFOC-20160701785,JANSSEN,,54.0,YR,A,M,Y,140.0,KG,20160707.0,,MD,GB,GB,2016,Q3,Adult
125370981,12537098,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q3,VIth nerve paralysis,,2016,Q3,1,I,20160413.0,20160701.0,20160707,20160707,EXP,,GB-JNJFOC-20160701785,JANSSEN,,54.0,YR,A,M,Y,140.0,KG,20160707.0,,MD,GB,GB,2016,Q3,Adult
125448781,12544878,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DRUG WAS STARTED APPROXIMATELY 8 MONTHS AGO (AT THE TIME OF THE REPORT),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160705.0,20160711,20160711,EXP,,PK-JNJFOC-20160704234,JANSSEN,"BADER N, MIRZA L. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A 27 YEAR-OLD FEMALE PATIENT WITH TYPE-1-DIABETES TREATED WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR CANAGLIFLOZIN. PAKISTAN JOURNAL OF MEDICAL SCIENCES 2016;32/3:786-788.",27.0,YR,A,F,Y,,,20160711.0,,OT,PK,US,2016,Q3,Young Adult
125448781,12544878,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DRUG WAS STARTED APPROXIMATELY 8 MONTHS AGO (AT THE TIME OF THE REPORT),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Off label use,,2016,Q3,1,I,,20160705.0,20160711,20160711,EXP,,PK-JNJFOC-20160704234,JANSSEN,"BADER N, MIRZA L. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A 27 YEAR-OLD FEMALE PATIENT WITH TYPE-1-DIABETES TREATED WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR CANAGLIFLOZIN. PAKISTAN JOURNAL OF MEDICAL SCIENCES 2016;32/3:786-788.",27.0,YR,A,F,Y,,,20160711.0,,OT,PK,US,2016,Q3,Young Adult
125448781,12544878,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DRUG WAS STARTED APPROXIMATELY 8 MONTHS AGO (AT THE TIME OF THE REPORT),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Product use issue,,2016,Q3,1,I,,20160705.0,20160711,20160711,EXP,,PK-JNJFOC-20160704234,JANSSEN,"BADER N, MIRZA L. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A 27 YEAR-OLD FEMALE PATIENT WITH TYPE-1-DIABETES TREATED WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR CANAGLIFLOZIN. PAKISTAN JOURNAL OF MEDICAL SCIENCES 2016;32/3:786-788.",27.0,YR,A,F,Y,,,20160711.0,,OT,PK,US,2016,Q3,Young Adult
125454051,12545405,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q3,Sunburn,,2016,Q3,1,I,,20160630.0,20160711,20160711,PER,,US-ACTELION-A-US2016-138808,ACTELION,,53.0,YR,A,F,Y,,,20160711.0,,MD,US,US,2016,Q3,Adult
125491471,12549147,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,150.958,DF,,,,,,1.0,DF,,QD,2016,Q3,Back pain,,2016,Q3,1,I,20160624.0,20160704.0,20160712,20160712,EXP,,GB-ASTRAZENECA-2016SE72860,ASTRAZENECA,,65.0,YR,,M,Y,63.0,KG,20160712.0,,MD,GB,GB,2016,Q3,Elderly
125491471,12549147,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,150.958,DF,,,,,,1.0,DF,,QD,2016,Q3,Penile pain,,2016,Q3,1,I,20160624.0,20160704.0,20160712,20160712,EXP,,GB-ASTRAZENECA-2016SE72860,ASTRAZENECA,,65.0,YR,,M,Y,63.0,KG,20160712.0,,MD,GB,GB,2016,Q3,Elderly
125491471,12549147,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,150.958,DF,,,,,,1.0,DF,,QD,2016,Q3,Urinary tract infection,,2016,Q3,1,I,20160624.0,20160704.0,20160712,20160712,EXP,,GB-ASTRAZENECA-2016SE72860,ASTRAZENECA,,65.0,YR,,M,Y,63.0,KG,20160712.0,,MD,GB,GB,2016,Q3,Elderly
125589861,12558986,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160701.0,20160713.0,20160715,20160715,EXP,,GB-JNJFOC-20160711301,JANSSEN,,40.0,YR,A,M,Y,,,20160715.0,,MD,GB,GB,2016,Q3,Adult
125589861,12558986,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2016,Q3,Vomiting,,2016,Q3,1,I,20160701.0,20160713.0,20160715,20160715,EXP,,GB-JNJFOC-20160711301,JANSSEN,,40.0,YR,A,M,Y,,,20160715.0,,MD,GB,GB,2016,Q3,Adult
125606661,12560666,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,1000.0,MG,UNKNOWN,BID,2016,Q3,Alopecia,,2016,Q3,1,I,20160501.0,20160602.0,20160715,20160715,PER,,US-JNJFOC-20160604532,JANSSEN,,48.0,YR,A,F,Y,87.09,KG,20160715.0,,CN,US,US,2016,Q3,Adult
125606661,12560666,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,1000.0,MG,UNKNOWN,BID,2016,Q3,Drug ineffective,,2016,Q3,1,I,20160501.0,20160602.0,20160715,20160715,PER,,US-JNJFOC-20160604532,JANSSEN,,48.0,YR,A,F,Y,87.09,KG,20160715.0,,CN,US,US,2016,Q3,Adult
125606661,12560666,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,1000.0,MG,UNKNOWN,BID,2016,Q3,Product formulation issue,,2016,Q3,1,I,20160501.0,20160602.0,20160715,20160715,PER,,US-JNJFOC-20160604532,JANSSEN,,48.0,YR,A,F,Y,87.09,KG,20160715.0,,CN,US,US,2016,Q3,Adult
125606661,12560666,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,1000.0,MG,UNKNOWN,BID,2016,Q3,Product odour abnormal,,2016,Q3,1,I,20160501.0,20160602.0,20160715,20160715,PER,,US-JNJFOC-20160604532,JANSSEN,,48.0,YR,A,F,Y,87.09,KG,20160715.0,,CN,US,US,2016,Q3,Adult
125654903,12565490,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Pericardial effusion,,2016,Q3,3,F,20160419.0,20160818.0,20160718,20160822,EXP,,CA-JNJFOC-20160427579,JANSSEN,,73.0,YR,E,F,Y,65.0,KG,20160822.0,,MD,CA,CA,2016,Q3,Elderly
125654903,12565490,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Varices oesophageal,,2016,Q3,3,F,20160419.0,20160818.0,20160718,20160822,EXP,,CA-JNJFOC-20160427579,JANSSEN,,73.0,YR,E,F,Y,65.0,KG,20160822.0,,MD,CA,CA,2016,Q3,Elderly
125682031,12568203,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q3,Burning sensation,,2016,Q3,1,I,,20160629.0,20160718,20160718,PER,,US-ACTELION-A-US2016-138930,ACTELION,,53.0,YR,A,M,Y,,,20160718.0,,MD,US,US,2016,Q3,Adult
125682031,12568203,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2016,Q3,Skin disorder,,2016,Q3,1,I,,20160629.0,20160718,20160718,PER,,US-ACTELION-A-US2016-138930,ACTELION,,53.0,YR,A,M,Y,,,20160718.0,,MD,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Abdominal pain upper,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Crohn's disease,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Drug dose omission,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Gastrointestinal haemorrhage,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Haematuria,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Incorrect product storage,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Intestinal haemorrhage,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Pain in extremity,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125712521,12571252,4,SS,Canagliflozin,CANAGLIFLOZIN,1,,DAILY,,,Y,U,,,,,,,,2016,Q3,Pyrexia,,2016,Q3,1,I,2016.0,20160503.0,20160719,20160719,EXP,,US-UCBSA-2016016667,UCB,,37.0,YR,,M,Y,102.0,KG,20160719.0,,CN,US,US,2016,Q3,Adult
125730703,12573070,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2016,Q3,Depression,,2016,Q3,3,F,20160624.0,20160912.0,20160720,20160915,EXP,,ES-ROCHE-1796698,ROCHE,,61.0,YR,,F,Y,94.0,KG,20160915.0,,MD,ES,ES,2016,Q3,Adult
125730703,12573070,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2016,Q3,Headache,,2016,Q3,3,F,20160624.0,20160912.0,20160720,20160915,EXP,,ES-ROCHE-1796698,ROCHE,,61.0,YR,,F,Y,94.0,KG,20160915.0,,MD,ES,ES,2016,Q3,Adult
125730703,12573070,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2016,Q3,Suicidal ideation,,2016,Q3,3,F,20160624.0,20160912.0,20160720,20160915,EXP,,ES-ROCHE-1796698,ROCHE,,61.0,YR,,F,Y,94.0,KG,20160915.0,,MD,ES,ES,2016,Q3,Adult
125739802,12573980,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Blood ketone body increased,,2016,Q3,2,F,201601.0,20160804.0,20160720,20160810,EXP,,GB-JNJFOC-20160714452,JANSSEN,,4.0,DEC,A,M,Y,125.3,KG,20160810.0,,OT,GB,GB,2016,Q3,Child
125807051,12580705,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, DAILY",,,Y,,,,,300.0,MG,,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160721,20160721,EXP,,JP-WATSON-2016-15884,WATSON,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016;55(13):1755-1760.",60.0,YR,,M,Y,72.8,KG,20160721.0,,MD,JP,JP,2016,Q3,Adult
125807051,12580705,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, DAILY",,,Y,,,,,300.0,MG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160721,20160721,EXP,,JP-WATSON-2016-15884,WATSON,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016;55(13):1755-1760.",60.0,YR,,M,Y,72.8,KG,20160721.0,,MD,JP,JP,2016,Q3,Adult
125808191,12580819,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,204042.0,,,CAPSULE,,2016,Q3,Penile abscess,,2016,Q3,1,I,20150421.0,20160707.0,20160721,20160721,EXP,,ES-JNJFOC-20160717186,JANSSEN,,57.0,YR,A,M,Y,,,20160721.0,,MD,ES,ES,2016,Q3,Adult
125808191,12580819,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,204042.0,,,CAPSULE,,2016,Q3,Penile prosthesis insertion,,2016,Q3,1,I,20150421.0,20160707.0,20160721,20160721,EXP,,ES-JNJFOC-20160717186,JANSSEN,,57.0,YR,A,M,Y,,,20160721.0,,MD,ES,ES,2016,Q3,Adult
125808191,12580819,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,76479.0,300.0,MG,CAPSULE,,2016,Q3,Penile abscess,,2016,Q3,1,I,20150421.0,20160707.0,20160721,20160721,EXP,,ES-JNJFOC-20160717186,JANSSEN,,57.0,YR,A,M,Y,,,20160721.0,,MD,ES,ES,2016,Q3,Adult
125808191,12580819,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 3250076;4368665,,76479.0,300.0,MG,CAPSULE,,2016,Q3,Penile prosthesis insertion,,2016,Q3,1,I,20150421.0,20160707.0,20160721,20160721,EXP,,ES-JNJFOC-20160717186,JANSSEN,,57.0,YR,A,M,Y,,,20160721.0,,MD,ES,ES,2016,Q3,Adult
125808203,12580820,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,3,F,,20160720.0,20160721,20160802,EXP,,JP-JNJFOC-20160716430,JANSSEN,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR.. INTERNAL MEDICINE 2016;55/13:1755-1760.",60.0,YR,A,M,Y,72.8,KG,20160802.0,,MD,JP,JP,2016,Q3,Adult
125808203,12580820,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q3,Intestinal ischaemia,,2016,Q3,3,F,,20160720.0,20160721,20160802,EXP,,JP-JNJFOC-20160716430,JANSSEN,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR.. INTERNAL MEDICINE 2016;55/13:1755-1760.",60.0,YR,A,M,Y,72.8,KG,20160802.0,,MD,JP,JP,2016,Q3,Adult
125808203,12580820,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q3,Lactic acidosis,,2016,Q3,3,F,,20160720.0,20160721,20160802,EXP,,JP-JNJFOC-20160716430,JANSSEN,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR.. INTERNAL MEDICINE 2016;55/13:1755-1760.",60.0,YR,A,M,Y,72.8,KG,20160802.0,,MD,JP,JP,2016,Q3,Adult
125815201,12581520,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160721,20160721,EXP,,JP-BAUSCH-BL-2016-017249,BAUSCH AND LOMB,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERNAL MEDICINE. 2016;55(13):1755-1760.",60.0,YR,,M,Y,72.8,KG,20160721.0,,MD,JP,JP,2016,Q3,Adult
125815201,12581520,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160721,20160721,EXP,,JP-BAUSCH-BL-2016-017249,BAUSCH AND LOMB,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERNAL MEDICINE. 2016;55(13):1755-1760.",60.0,YR,,M,Y,72.8,KG,20160721.0,,MD,JP,JP,2016,Q3,Adult
125823731,12582373,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160718.0,20160722,20160722,EXP,,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023701",GLENMARK,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR.INTERNAL MEDICINE. 2016;55(13):1755-1760",60.0,YR,,M,Y,72.8,KG,20160722.0,,MD,JP,JP,2016,Q3,Adult
125823731,12582373,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,Y,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160718.0,20160722,20160722,EXP,,"JP-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023701",GLENMARK,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR.INTERNAL MEDICINE. 2016;55(13):1755-1760",60.0,YR,,M,Y,72.8,KG,20160722.0,,MD,JP,JP,2016,Q3,Adult
125833611,12583361,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2016,Q3,Drug ineffective,,2016,Q3,1,I,,20160711.0,20160722,20160722,PER,,US-BAYER-2016-137781,BAYER,,68.0,YR,E,M,Y,97.51,KG,20160722.0,,CN,US,US,2016,Q3,Elderly
125833611,12583361,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2016,Q3,Somnolence,,2016,Q3,1,I,,20160711.0,20160722,20160722,PER,,US-BAYER-2016-137781,BAYER,,68.0,YR,E,M,Y,97.51,KG,20160722.0,,CN,US,US,2016,Q3,Elderly
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Disseminated intravascular coagulation,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Gastrointestinal necrosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Intestinal ischaemia,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860141,12586014,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Shock,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INDICUS PHARMA-000433,INDICUS,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860621,12586062,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,Y,U,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-120747,RANBAXY,,60.0,YR,,M,Y,72.8,KG,20160725.0,,OT,GB,JP,2016,Q3,Adult
125860621,12586062,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,Y,U,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-120747,RANBAXY,,60.0,YR,,M,Y,72.8,KG,20160725.0,,OT,GB,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Disseminated intravascular coagulation,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Gastrointestinal necrosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Intestinal ischaemia,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125860651,12586065,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Shock,,2016,Q3,1,I,,20160711.0,20160725,20160725,EXP,,JP-INVENTIA-000131,INVENTIA HEALTHCARE,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, ET AL. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED. 2016; 55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160725.0,,MD,JP,JP,2016,Q3,Adult
125923711,12592371,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160711.0,20160720.0,20160726,20160726,EXP,,GB-JNJFOC-20160717162,JANSSEN,,77.0,YR,E,M,Y,,,20160726.0,,MD,GB,GB,2016,Q3,Elderly
125923711,12592371,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Urinary tract infection,,2016,Q3,1,I,20160711.0,20160720.0,20160726,20160726,EXP,,GB-JNJFOC-20160717162,JANSSEN,,77.0,YR,E,M,Y,,,20160726.0,,MD,GB,GB,2016,Q3,Elderly
125940791,12594079,2,SS,Canagliflozin,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160711.0,20160726,20160726,EXP,,JP-IPCA LABORATORIES LIMITED-IPC201607-000635,IPCA,"GOCHO N,AOKI E,OKADA C,OMURA K,HIRASHIMA T,SUZUKI N. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED 2016;55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160726.0,,MD,JP,JP,2016,Q3,Adult
125940791,12594079,2,SS,Canagliflozin,CANAGLIFLOZIN,1,,,,,Y,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160711.0,20160726,20160726,EXP,,JP-IPCA LABORATORIES LIMITED-IPC201607-000635,IPCA,"GOCHO N,AOKI E,OKADA C,OMURA K,HIRASHIMA T,SUZUKI N. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERN MED 2016;55(13):1755-60.",60.0,YR,,M,Y,72.8,KG,20160726.0,,MD,JP,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Dehydration,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Diabetes mellitus inadequate control,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Drug prescribing error,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Exploratory operation,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Haemodialysis,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Intestinal ischaemia,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Intestinal resection,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125995371,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2016,Q3,Weight decreased,,2016,Q3,1,I,,20160713.0,20160727,20160727,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20160727.0,,CN,GB,JP,2016,Q3,Adult
125996341,12599634,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160719.0,20160727,20160727,EXP,,PHHY2016JP099208,SANDOZ,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL.. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERNAL MEDICINE. 2016;55(13):1755-60",60.0,YR,,M,Y,72.8,KG,20160727.0,,OT,JP,JP,2016,Q3,Adult
125996341,12599634,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,300.0,MG,,,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160719.0,20160727,20160727,EXP,,PHHY2016JP099208,SANDOZ,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N ET AL.. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERNAL MEDICINE. 2016;55(13):1755-60",60.0,YR,,M,Y,72.8,KG,20160727.0,,OT,JP,JP,2016,Q3,Adult
126112642,12611264,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 37309627,,204042.0,,,CAPSULE,,2016,Q3,Cerebrovascular accident,,2016,Q3,2,F,20160707.0,20160801.0,20160801,20160803,EXP,,CZ-JNJFOC-20160723502,JANSSEN,,73.0,YR,E,M,Y,117.0,KG,20160803.0,,MD,CZ,CZ,2016,Q3,Elderly
126112642,12611264,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 OR 300 MG,,,,N, 37309627,,76479.0,,,CAPSULE,,2016,Q3,Cerebrovascular accident,,2016,Q3,2,F,20160707.0,20160801.0,20160801,20160803,EXP,,CZ-JNJFOC-20160723502,JANSSEN,,73.0,YR,E,M,Y,117.0,KG,20160803.0,,MD,CZ,CZ,2016,Q3,Elderly
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Amylase increased,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Disseminated intravascular coagulation,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Gastrointestinal necrosis,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Haemodialysis,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Intestinal ischaemia,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Lactic acidosis,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Lipase increased,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126221911,12622191,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,Y,,,,,300.0,MG,,QD,2016,Q3,Shock,,2016,Q3,1,I,,20160718.0,20160804,20160804,EXP,JP-MLMSERVICE-20160712-0351467-1,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2016-00080,ALKEM,,60.0,YR,,M,Y,72.8,KG,20160804.0,,MD,JP,JP,2016,Q3,Adult
126294223,12629422,14,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MG, ONCE DAILY (QD)",,,,U,,,,300.0,MG,,QD,2016,Q3,Blood glucose increased,,2016,Q3,3,F,20160731.0,20160816.0,20160808,20160823,EXP,,US-UCBSA-2016029246,UCB,,67.0,YR,,F,Y,102.0,KG,20160823.0,,OT,US,US,2016,Q3,Elderly
126294223,12629422,14,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MG, ONCE DAILY (QD)",,,,U,,,,300.0,MG,,QD,2016,Q3,Dyspnoea,,2016,Q3,3,F,20160731.0,20160816.0,20160808,20160823,EXP,,US-UCBSA-2016029246,UCB,,67.0,YR,,F,Y,102.0,KG,20160823.0,,OT,US,US,2016,Q3,Elderly
126294223,12629422,14,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MG, ONCE DAILY (QD)",,,,U,,,,300.0,MG,,QD,2016,Q3,Hypertension,,2016,Q3,3,F,20160731.0,20160816.0,20160808,20160823,EXP,,US-UCBSA-2016029246,UCB,,67.0,YR,,F,Y,102.0,KG,20160823.0,,OT,US,US,2016,Q3,Elderly
126294223,12629422,14,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MG, ONCE DAILY (QD)",,,,U,,,,300.0,MG,,QD,2016,Q3,Myocardial infarction,,2016,Q3,3,F,20160731.0,20160816.0,20160808,20160823,EXP,,US-UCBSA-2016029246,UCB,,67.0,YR,,F,Y,102.0,KG,20160823.0,,OT,US,US,2016,Q3,Elderly
126294223,12629422,14,C,Canagliflozin,CANAGLIFLOZIN,1,Oral,"300 MG, ONCE DAILY (QD)",,,,U,,,,300.0,MG,,QD,2016,Q3,Peripheral swelling,,2016,Q3,3,F,20160731.0,20160816.0,20160808,20160823,EXP,,US-UCBSA-2016029246,UCB,,67.0,YR,,F,Y,102.0,KG,20160823.0,,OT,US,US,2016,Q3,Elderly
126300112,12630011,1,PS,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,2,F,201607.0,20160805.0,20160808,20160811,EXP,,IN-JNJFOC-20160804130,JANSSEN,,63.0,YR,,F,Y,,,20160811.0,,MD,IN,IN,2016,Q3,Adult
126300112,12630011,1,PS,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Pyrexia,,2016,Q3,2,F,201607.0,20160805.0,20160808,20160811,EXP,,IN-JNJFOC-20160804130,JANSSEN,,63.0,YR,,F,Y,,,20160811.0,,MD,IN,IN,2016,Q3,Adult
126423091,12642309,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,,300.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160802.0,20160810,20160810,EXP,,US-JNJFOC-20160802917,JANSSEN,"JUAREZ RAMIREZ TELLO EM, MENFIL OA, NUGENT K. SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR-INDUCED DIABETIC KETOACIDOSIS IN A TYPE 2 DIABETIC PATIENT. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. VOLUME 351 NUMBER 6 JUNE 2016 JUN-2016;351/6:634-635.",36.0,YR,A,M,Y,,,20160810.0,,MD,US,US,2016,Q3,Adult
126423091,12642309,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160802.0,20160810,20160810,EXP,,US-JNJFOC-20160802917,JANSSEN,"JUAREZ RAMIREZ TELLO EM, MENFIL OA, NUGENT K. SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR-INDUCED DIABETIC KETOACIDOSIS IN A TYPE 2 DIABETIC PATIENT. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. VOLUME 351 NUMBER 6 JUNE 2016 JUN-2016;351/6:634-635.",36.0,YR,A,M,Y,,,20160810.0,,MD,US,US,2016,Q3,Adult
126689711,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Blood glucose abnormal,,2016,Q3,1,I,2016.0,20160812.0,20160819,20160819,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20160819.0,,MD,GB,GB,2016,Q3,Adult
126689711,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,2016.0,20160812.0,20160819,20160819,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20160819.0,,MD,GB,GB,2016,Q3,Adult
126689711,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Fatigue,,2016,Q3,1,I,2016.0,20160812.0,20160819,20160819,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20160819.0,,MD,GB,GB,2016,Q3,Adult
126689711,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Polydipsia,,2016,Q3,1,I,2016.0,20160812.0,20160819,20160819,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20160819.0,,MD,GB,GB,2016,Q3,Adult
126792151,12679215,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160812.0,20160824,20160824,EXP,GB-MHRA-ADR 23595395,GB-ALVOGEN-2016-ALVOGEN-027865,ALVOGEN,,52.0,YR,,M,Y,,,20160824.0,,PH,GB,GB,2016,Q3,Adult
126792151,12679215,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Dehydration,,2016,Q3,1,I,,20160812.0,20160824,20160824,EXP,GB-MHRA-ADR 23595395,GB-ALVOGEN-2016-ALVOGEN-027865,ALVOGEN,,52.0,YR,,M,Y,,,20160824.0,,PH,GB,GB,2016,Q3,Adult
126792151,12679215,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Diarrhoea,,2016,Q3,1,I,,20160812.0,20160824,20160824,EXP,GB-MHRA-ADR 23595395,GB-ALVOGEN-2016-ALVOGEN-027865,ALVOGEN,,52.0,YR,,M,Y,,,20160824.0,,PH,GB,GB,2016,Q3,Adult
126792151,12679215,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Nephropathy toxic,,2016,Q3,1,I,,20160812.0,20160824,20160824,EXP,GB-MHRA-ADR 23595395,GB-ALVOGEN-2016-ALVOGEN-027865,ALVOGEN,,52.0,YR,,M,Y,,,20160824.0,,PH,GB,GB,2016,Q3,Adult
126792151,12679215,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Vomiting,,2016,Q3,1,I,,20160812.0,20160824,20160824,EXP,GB-MHRA-ADR 23595395,GB-ALVOGEN-2016-ALVOGEN-027865,ALVOGEN,,52.0,YR,,M,Y,,,20160824.0,,PH,GB,GB,2016,Q3,Adult
126796991,12679699,1,PS,"CANAGLIFLOZIN, 100MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,600.0,MG,,QD,2016,Q3,Ankle fracture,,2016,Q3,1,I,20160820.0,,20160823,20160823,DIR,,,,,73.0,YR,,M,N,110.0,KG,20160822.0,N,PH,US,,2016,Q3,Elderly
126796991,12679699,1,PS,"CANAGLIFLOZIN, 100MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,600.0,MG,,QD,2016,Q3,Fall,,2016,Q3,1,I,20160820.0,,20160823,20160823,DIR,,,,,73.0,YR,,M,N,110.0,KG,20160822.0,N,PH,US,,2016,Q3,Elderly
126796991,12679699,1,PS,"CANAGLIFLOZIN, 100MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,600.0,MG,,QD,2016,Q3,Fracture,,2016,Q3,1,I,20160820.0,,20160823,20160823,DIR,,,,,73.0,YR,,M,N,110.0,KG,20160822.0,N,PH,US,,2016,Q3,Elderly
126830081,12683008,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,,GB-AUROBINDO-AUR-APL-2016-10544,AUROBINDO,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126830081,12683008,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q3,Dehydration,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,,GB-AUROBINDO-AUR-APL-2016-10544,AUROBINDO,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126830081,12683008,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q3,Diarrhoea,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,,GB-AUROBINDO-AUR-APL-2016-10544,AUROBINDO,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126830081,12683008,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q3,Nephropathy toxic,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,,GB-AUROBINDO-AUR-APL-2016-10544,AUROBINDO,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126830081,12683008,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q3,Vomiting,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,,GB-AUROBINDO-AUR-APL-2016-10544,AUROBINDO,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126836571,12683657,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Activities of daily living impaired,,2016,Q3,1,I,20151011.0,,20160824,20160824,DIR,,,,,47.0,YR,,M,N,210.0,LBS,20160823.0,N,PH,US,,2016,Q3,Adult
126836571,12683657,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Anxiety,,2016,Q3,1,I,20151011.0,,20160824,20160824,DIR,,,,,47.0,YR,,M,N,210.0,LBS,20160823.0,N,PH,US,,2016,Q3,Adult
126836571,12683657,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Hallucination,,2016,Q3,1,I,20151011.0,,20160824,20160824,DIR,,,,,47.0,YR,,M,N,210.0,LBS,20160823.0,N,PH,US,,2016,Q3,Adult
126836571,12683657,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Impaired work ability,,2016,Q3,1,I,20151011.0,,20160824,20160824,DIR,,,,,47.0,YR,,M,N,210.0,LBS,20160823.0,N,PH,US,,2016,Q3,Adult
126836571,12683657,1,PS,"CANAGLIFLOZIN, 100 MG",CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Paranoia,,2016,Q3,1,I,20151011.0,,20160824,20160824,DIR,,,,,47.0,YR,,M,N,210.0,LBS,20160823.0,N,PH,US,,2016,Q3,Adult
126851491,12685149,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,GB-MHRA-EYC 00143578,GB-TEVA-685580ACC,TEVA,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126851491,12685149,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Dehydration,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,GB-MHRA-EYC 00143578,GB-TEVA-685580ACC,TEVA,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126851491,12685149,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Diarrhoea,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,GB-MHRA-EYC 00143578,GB-TEVA-685580ACC,TEVA,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126851491,12685149,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Nephropathy toxic,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,GB-MHRA-EYC 00143578,GB-TEVA-685580ACC,TEVA,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126851491,12685149,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q3,Vomiting,,2016,Q3,1,I,,20160812.0,20160825,20160825,EXP,GB-MHRA-EYC 00143578,GB-TEVA-685580ACC,TEVA,,52.0,YR,,M,Y,,,20160825.0,,PH,GB,GB,2016,Q3,Adult
126885331,12688533,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160812.0,20160826,20160826,EXP,GB-MHRA-EYC 00143578,GB-LUPIN PHARMACEUTICALS INC.-E2B_00006011,LUPIN,,52.0,YR,,M,Y,,,20160826.0,,,GB,GB,2016,Q3,Adult
126885331,12688533,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q3,Dehydration,,2016,Q3,1,I,,20160812.0,20160826,20160826,EXP,GB-MHRA-EYC 00143578,GB-LUPIN PHARMACEUTICALS INC.-E2B_00006011,LUPIN,,52.0,YR,,M,Y,,,20160826.0,,,GB,GB,2016,Q3,Adult
126885331,12688533,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q3,Diarrhoea,,2016,Q3,1,I,,20160812.0,20160826,20160826,EXP,GB-MHRA-EYC 00143578,GB-LUPIN PHARMACEUTICALS INC.-E2B_00006011,LUPIN,,52.0,YR,,M,Y,,,20160826.0,,,GB,GB,2016,Q3,Adult
126885331,12688533,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q3,Nephropathy toxic,,2016,Q3,1,I,,20160812.0,20160826,20160826,EXP,GB-MHRA-EYC 00143578,GB-LUPIN PHARMACEUTICALS INC.-E2B_00006011,LUPIN,,52.0,YR,,M,Y,,,20160826.0,,,GB,GB,2016,Q3,Adult
126885331,12688533,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2016,Q3,Vomiting,,2016,Q3,1,I,,20160812.0,20160826,20160826,EXP,GB-MHRA-EYC 00143578,GB-LUPIN PHARMACEUTICALS INC.-E2B_00006011,LUPIN,,52.0,YR,,M,Y,,,20160826.0,,,GB,GB,2016,Q3,Adult
126899671,12689967,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160823.0,20160826,20160826,EXP,,CA-JNJFOC-20160820321,JANSSEN,"ANDALIB A, ELBAHRAWY A, ALSHLWI S, ALKHAMIS A, HU W, DEMYTTENAERE S, ET AL. DIABETIC KETOACIDOSIS FOLLOWING BARIATRIC SURGERY IN PATIENTS WITH TYPE 2 DIABETES. DIABETES CARE 2016;39:E121-E122.",58.0,YR,A,M,Y,,,20160826.0,,OT,CA,CA,2016,Q3,Adult
127064961,12706496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,201401.0,20160824.0,20160901,20160901,EXP,,US-JNJFOC-20160824120,JANSSEN,,53.0,YR,A,F,Y,,,20160901.0,,CN,US,US,2016,Q3,Adult
127064961,12706496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Pyelonephritis acute,,2016,Q3,1,I,201401.0,20160824.0,20160901,20160901,EXP,,US-JNJFOC-20160824120,JANSSEN,,53.0,YR,A,F,Y,,,20160901.0,,CN,US,US,2016,Q3,Adult
127064961,12706496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Sepsis,,2016,Q3,1,I,201401.0,20160824.0,20160901,20160901,EXP,,US-JNJFOC-20160824120,JANSSEN,,53.0,YR,A,F,Y,,,20160901.0,,CN,US,US,2016,Q3,Adult
127108351,12710835,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,300.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160311.0,20160502.0,20160902,20160902,PER,,US-JNJFOC-20160502509,JANSSEN,,44.0,YR,A,F,Y,95.3,KG,20160902.0,,PH,US,US,2016,Q3,Adult
127108351,12710835,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160311.0,20160502.0,20160902,20160902,PER,,US-JNJFOC-20160502509,JANSSEN,,44.0,YR,A,F,Y,95.3,KG,20160902.0,,PH,US,US,2016,Q3,Adult
127205891,12720589,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,Y,,,,,300.0,MG,,,2016,Q3,Acute kidney injury,,2016,Q3,1,I,,20160902.0,20160907,20160907,EXP,,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00401,SCIEGEN,,51.0,YR,,F,Y,,,20160907.0,,MD,IE,US,2016,Q3,Adult
127205891,12720589,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,Y,,,,,300.0,MG,,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,,20160902.0,20160907,20160907,EXP,,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00401,SCIEGEN,,51.0,YR,,F,Y,,,20160907.0,,MD,IE,US,2016,Q3,Adult
127205891,12720589,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,Y,,,,,300.0,MG,,,2016,Q3,Presyncope,,2016,Q3,1,I,,20160902.0,20160907,20160907,EXP,,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00401,SCIEGEN,,51.0,YR,,F,Y,,,20160907.0,,MD,IE,US,2016,Q3,Adult
127205891,12720589,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,Y,,,,,300.0,MG,,,2016,Q3,Sinus tachycardia,,2016,Q3,1,I,,20160902.0,20160907,20160907,EXP,,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00401,SCIEGEN,,51.0,YR,,F,Y,,,20160907.0,,MD,IE,US,2016,Q3,Adult
127207592,12720759,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,2,F,,20160921.0,20160907,20160928,EXP,,IN-JNJFOC-20160901663,JANSSEN,,38.0,YR,A,F,Y,97.0,KG,20160928.0,,CN,IN,IN,2016,Q3,Adult
127207592,12720759,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Dialysis,,2016,Q3,2,F,,20160921.0,20160907,20160928,EXP,,IN-JNJFOC-20160901663,JANSSEN,,38.0,YR,A,F,Y,97.0,KG,20160928.0,,CN,IN,IN,2016,Q3,Adult
127207592,12720759,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Weight decreased,,2016,Q3,2,F,,20160921.0,20160907,20160928,EXP,,IN-JNJFOC-20160901663,JANSSEN,,38.0,YR,A,F,Y,97.0,KG,20160928.0,,CN,IN,IN,2016,Q3,Adult
127377821,12737782,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160820.0,20160906.0,20160913,20160913,EXP,,GB-JNJFOC-20160905553,JANSSEN,,75.0,YR,E,M,Y,70.0,KG,20160913.0,,MD,GB,GB,2016,Q3,Elderly
127377821,12737782,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2016,Q3,Large intestinal obstruction,,2016,Q3,1,I,20160820.0,20160906.0,20160913,20160913,EXP,,GB-JNJFOC-20160905553,JANSSEN,,75.0,YR,E,M,Y,70.0,KG,20160913.0,,MD,GB,GB,2016,Q3,Elderly
127394171,12739417,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370382,,204042.0,,,CAPSULE,,2016,Q3,Polymyalgia rheumatica,,2016,Q3,1,I,201603.0,20160905.0,20160913,20160913,EXP,,DE-JNJFOC-20160904404,JANSSEN,,80.0,YR,E,M,Y,75.1,KG,20160913.0,,MD,DE,DE,2016,Q3,Elderly
127394171,12739417,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4370382,,76479.0,300.0,MG,CAPSULE,QD,2016,Q3,Polymyalgia rheumatica,,2016,Q3,1,I,201603.0,20160905.0,20160913,20160913,EXP,,DE-JNJFOC-20160904404,JANSSEN,,80.0,YR,E,M,Y,75.1,KG,20160913.0,,MD,DE,DE,2016,Q3,Elderly
127397072,12739707,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 3087363,,204042.0,,,CAPSULE,,2016,Q3,Leg amputation,,2016,Q3,2,F,20160831.0,20160919.0,20160913,20160927,EXP,,NL-JNJFOC-20160904391,JANSSEN,,65.0,YR,A,M,Y,,,20160927.0,,MD,NL,NL,2016,Q3,Elderly
127397072,12739707,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 3087363,,204042.0,,,CAPSULE,,2016,Q3,Peripheral arterial occlusive disease,,2016,Q3,2,F,20160831.0,20160919.0,20160913,20160927,EXP,,NL-JNJFOC-20160904391,JANSSEN,,65.0,YR,A,M,Y,,,20160927.0,,MD,NL,NL,2016,Q3,Elderly
127397072,12739707,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100/300 MG,,,,N, 3087363,,76479.0,100.0,MG,CAPSULE,QD,2016,Q3,Leg amputation,,2016,Q3,2,F,20160831.0,20160919.0,20160913,20160927,EXP,,NL-JNJFOC-20160904391,JANSSEN,,65.0,YR,A,M,Y,,,20160927.0,,MD,NL,NL,2016,Q3,Elderly
127397072,12739707,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100/300 MG,,,,N, 3087363,,76479.0,100.0,MG,CAPSULE,QD,2016,Q3,Peripheral arterial occlusive disease,,2016,Q3,2,F,20160831.0,20160919.0,20160913,20160927,EXP,,NL-JNJFOC-20160904391,JANSSEN,,65.0,YR,A,M,Y,,,20160927.0,,MD,NL,NL,2016,Q3,Elderly
127422711,12742271,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2016,Q3,Acetonaemia,,2016,Q3,1,I,,20160906.0,20160914,20160914,EXP,,IN-JNJFOC-20160907446,JANSSEN,"GHOSH A, GUPTA R, MISRA A. KETONURIA/KETONEMIA ASSOCIATED WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) INHIBITORS IN TYPE 2 DIABETES: A REPORT OF THREE CASES FROM NEW DELHI, INDIA. JOURNAL OF DIABETES 01-SEP-2016;8/5:738-739.",57.0,YR,A,M,Y,,,20160914.0,,MD,IN,IN,2016,Q3,Adult
127422711,12742271,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2016,Q3,Ketonuria,,2016,Q3,1,I,,20160906.0,20160914,20160914,EXP,,IN-JNJFOC-20160907446,JANSSEN,"GHOSH A, GUPTA R, MISRA A. KETONURIA/KETONEMIA ASSOCIATED WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) INHIBITORS IN TYPE 2 DIABETES: A REPORT OF THREE CASES FROM NEW DELHI, INDIA. JOURNAL OF DIABETES 01-SEP-2016;8/5:738-739.",57.0,YR,A,M,Y,,,20160914.0,,MD,IN,IN,2016,Q3,Adult
127422731,12742273,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2016,Q3,Ketonuria,,2016,Q3,1,I,,20160906.0,20160914,20160914,EXP,,IN-JNJFOC-20160908215,JANSSEN,"GHOSH A, GUPTA R, MISRA A. KETONURIA/KETONEMIA ASSOCIATED WITH THE USE OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) INHIBITORS IN TYPE 2 DIABETES: A REPORT OF THREE CASES FROM NEW DELHI, INDIA. JOURNAL OF DIABETES 01-SEP-2016;8/5:738-739.",60.0,YR,A,F,Y,,,20160914.0,,MD,IN,IN,2016,Q3,Adult
127462221,12746222,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, FKL2601,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160901.0,20160913.0,20160915,20160915,EXP,,GB-JNJFOC-20160913684,JANSSEN,,78.0,YR,E,F,Y,60.32,KG,20160915.0,,PH,GB,GB,2016,Q3,Elderly
127462221,12746222,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, FKL2601,,204042.0,,,TABLET,,2016,Q3,Dizziness,,2016,Q3,1,I,20160901.0,20160913.0,20160915,20160915,EXP,,GB-JNJFOC-20160913684,JANSSEN,,78.0,YR,E,F,Y,60.32,KG,20160915.0,,PH,GB,GB,2016,Q3,Elderly
127462221,12746222,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, FKL2601,,204042.0,,,TABLET,,2016,Q3,Fatigue,,2016,Q3,1,I,20160901.0,20160913.0,20160915,20160915,EXP,,GB-JNJFOC-20160913684,JANSSEN,,78.0,YR,E,F,Y,60.32,KG,20160915.0,,PH,GB,GB,2016,Q3,Elderly
127590771,12759077,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160817.0,20160912.0,20160919,20160919,EXP,,GB-JNJFOC-20160911454,JANSSEN,,49.0,YR,A,M,Y,,,20160919.0,,OT,GB,GB,2016,Q3,Adult
127590771,12759077,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,CAPSULE,,2016,Q3,Malaise,,2016,Q3,1,I,20160817.0,20160912.0,20160919,20160919,EXP,,GB-JNJFOC-20160911454,JANSSEN,,49.0,YR,A,M,Y,,,20160919.0,,OT,GB,GB,2016,Q3,Adult
127597971,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Conjunctivitis allergic,,2016,Q3,1,I,20160312.0,20160606.0,20160919,20160919,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20160919.0,,OT,JP,JP,2016,Q3,Elderly
127597971,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Diabetic retinopathy,,2016,Q3,1,I,20160312.0,20160606.0,20160919,20160919,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20160919.0,,OT,JP,JP,2016,Q3,Elderly
127597971,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Migraine,,2016,Q3,1,I,20160312.0,20160606.0,20160919,20160919,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20160919.0,,OT,JP,JP,2016,Q3,Elderly
127626751,12762675,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Urinary retention,,2016,Q3,1,I,,20160913.0,20160920,20160920,EXP,,GB-JNJFOC-20160912807,JANSSEN,,64.0,YR,A,M,Y,,,20160920.0,,PH,GB,GB,2016,Q3,Adult
127626751,12762675,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,,,TABLET,,2016,Q3,Urosepsis,,2016,Q3,1,I,,20160913.0,20160920,20160920,EXP,,GB-JNJFOC-20160912807,JANSSEN,,64.0,YR,A,M,Y,,,20160920.0,,PH,GB,GB,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Acidosis,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Acute kidney injury,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Dehydration,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Dialysis,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Diarrhoea,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Hyperkalaemia,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Hypophagia,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Nausea,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127977791,12797779,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q3,Vomiting,,2016,Q3,1,I,20160913.0,,20160929,20160929,DIR,US-FDA-351857,,FDA-CTU,,57.0,YR,,F,N,87.1,KG,20160929.0,N,MD,US,US,2016,Q3,Adult
127983991,12798399,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED) START PERIOD: 166 DAYS DURATION OF DRUG ADMIN.: 167 DAYS,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Abdominal discomfort,,2016,Q3,1,I,20160918.0,20160928.0,20160930,20160930,EXP,,GB-JNJFOC-20160928202,JANSSEN,,51.0,YR,A,F,Y,64.2,KG,20160930.0,,OT,GB,GB,2016,Q3,Adult
127983991,12798399,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED) START PERIOD: 166 DAYS DURATION OF DRUG ADMIN.: 167 DAYS,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160918.0,20160928.0,20160930,20160930,EXP,,GB-JNJFOC-20160928202,JANSSEN,,51.0,YR,A,F,Y,64.2,KG,20160930.0,,OT,GB,GB,2016,Q3,Adult
127983991,12798399,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED) START PERIOD: 166 DAYS DURATION OF DRUG ADMIN.: 167 DAYS,,,Y,U,,,204042.0,,,TABLET,,2016,Q3,Vomiting,,2016,Q3,1,I,20160918.0,20160928.0,20160930,20160930,EXP,,GB-JNJFOC-20160928202,JANSSEN,,51.0,YR,A,F,Y,64.2,KG,20160930.0,,OT,GB,GB,2016,Q3,Adult
127993651,12799365,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q3,Pneumonia,,2016,Q3,1,I,20160831.0,20160927.0,20160930,20160930,EXP,,JP-JNJFOC-20160930497,JANSSEN,,68.0,YR,E,M,Y,75.0,KG,20160930.0,,OT,JP,JP,2016,Q3,Elderly
128018661,12801866,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Decreased appetite,,2016,Q3,1,I,20160926.0,,20160930,20160930,DIR,US-FDA-351954,,FDA-CTU,,64.0,YR,,F,N,63.0,KG,20160930.0,N,PH,US,US,2016,Q3,Adult
128018661,12801866,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Diabetic ketoacidosis,,2016,Q3,1,I,20160926.0,,20160930,20160930,DIR,US-FDA-351954,,FDA-CTU,,64.0,YR,,F,N,63.0,KG,20160930.0,N,PH,US,US,2016,Q3,Adult
128018661,12801866,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Fatigue,,2016,Q3,1,I,20160926.0,,20160930,20160930,DIR,US-FDA-351954,,FDA-CTU,,64.0,YR,,F,N,63.0,KG,20160930.0,N,PH,US,US,2016,Q3,Adult
128018661,12801866,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q3,Nausea,,2016,Q3,1,I,20160926.0,,20160930,20160930,DIR,US-FDA-351954,,FDA-CTU,,64.0,YR,,F,N,63.0,KG,20160930.0,N,PH,US,US,2016,Q3,Adult
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Adenocarcinoma of colon,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Bladder cancer,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Colon adenoma,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Lung adenocarcinoma,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Malignant lymphoid neoplasm,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 365186;363184,,204042.0,,,CAPSULE,,2016,Q3,Prostatomegaly,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Adenocarcinoma of colon,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Bladder cancer,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Colon adenoma,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Lung adenocarcinoma,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Malignant lymphoid neoplasm,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
93755719,9375571,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 OR 300 MG,,,,N, 365186;363184,,76479.0,,,CAPSULE,,2016,Q3,Prostatomegaly,,2016,Q3,9,F,20130228.0,20160811.0,20130628,20160819,EXP,,NZ-JNJFOC-20130313440,JANSSEN,,77.0,YR,E,M,Y,72.0,KG,20160819.0,,OT,NZ,NZ,2016,Q3,Elderly
116168834,11616883,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B186322,,204042.0,,,CAPSULE,,2016,Q4,Perinephric abscess,,2016,Q4,4,F,20150507.0,20161213.0,20151009,20161221,EXP,,ES-JNJFOC-20150506677,JANSSEN,,72.0,YR,E,M,Y,82.5,KG,20161221.0,,MD,ES,ES,2016,Q4,Elderly
116168834,11616883,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B186322,,204042.0,,,CAPSULE,,2016,Q4,Septic shock,,2016,Q4,4,F,20150507.0,20161213.0,20151009,20161221,EXP,,ES-JNJFOC-20150506677,JANSSEN,,72.0,YR,E,M,Y,82.5,KG,20161221.0,,MD,ES,ES,2016,Q4,Elderly
116168834,11616883,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B186322,,76479.0,300.0,MG,CAPSULE,,2016,Q4,Perinephric abscess,,2016,Q4,4,F,20150507.0,20161213.0,20151009,20161221,EXP,,ES-JNJFOC-20150506677,JANSSEN,,72.0,YR,E,M,Y,82.5,KG,20161221.0,,MD,ES,ES,2016,Q4,Elderly
116168834,11616883,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, B186322,,76479.0,300.0,MG,CAPSULE,,2016,Q4,Septic shock,,2016,Q4,4,F,20150507.0,20161213.0,20151009,20161221,EXP,,ES-JNJFOC-20150506677,JANSSEN,,72.0,YR,E,M,Y,82.5,KG,20161221.0,,MD,ES,ES,2016,Q4,Elderly
118854543,11885454,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T195186,,204042.0,,,CAPSULE,,2016,Q4,Cardio-respiratory arrest,,2016,Q4,3,F,20151220.0,20161004.0,20160104,20161007,EXP,,IN-JNJFOC-20151224686,JANSSEN,,70.0,YR,E,M,Y,,,20161007.0,,MD,IN,IN,2016,Q4,Elderly
118854543,11885454,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 MG OR 300 MG,,,D,N, T195186,,76479.0,,,CAPSULE,,2016,Q4,Cardio-respiratory arrest,,2016,Q4,3,F,20151220.0,20161004.0,20160104,20161007,EXP,,IN-JNJFOC-20151224686,JANSSEN,,70.0,YR,E,M,Y,,,20161007.0,,MD,IN,IN,2016,Q4,Elderly
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Amputation,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Decubitus ulcer,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Diabetic foot,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Diabetic foot infection,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Respiratory failure,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,1,PS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,204042.0,100.0,MG,CAPSULE,QD,2016,Q4,Wound sepsis,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Amputation,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Decubitus ulcer,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Diabetic foot,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Diabetic foot infection,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Respiratory failure,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123147053,12314705,2,SS,blinded; CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 4368661,,76479.0,100.0,MG,CAPSULE,QD,2016,Q4,Wound sepsis,,2016,Q4,3,F,20151009.0,20161004.0,20160428,20161007,EXP,,NL-JNJFOC-20151011193,JANSSEN,,60.0,YR,A,F,Y,96.0,KG,20161007.0,,MD,NL,NL,2016,Q4,Adult
123236565,12323656,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, T203342,,204042.0,,,CAPSULE,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,5,F,20160426.0,20160928.0,20160502,20161010,EXP,,CA-JNJFOC-20160426484,JANSSEN,,82.0,YR,E,M,Y,74.3,KG,20161010.0,,MD,CA,CA,2016,Q4,Elderly
123236565,12323656,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE WAS 100 OR 300 MG,,,Y,N, T203342,,76479.0,,,CAPSULE,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,5,F,20160426.0,20160928.0,20160502,20161010,EXP,,CA-JNJFOC-20160426484,JANSSEN,,82.0,YR,E,M,Y,74.3,KG,20161010.0,,MD,CA,CA,2016,Q4,Elderly
124426692,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q4,Asthma,,2016,Q4,2,F,20160205.0,20161130.0,20160607,20161205,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20161205.0,,OT,CA,CA,2016,Q4,Young Adult
124426692,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q4,Photodermatosis,,2016,Q4,2,F,20160205.0,20161130.0,20160607,20161205,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20161205.0,,OT,CA,CA,2016,Q4,Young Adult
124426692,12442669,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2016,Q4,Vulvovaginal candidiasis,,2016,Q4,2,F,20160205.0,20161130.0,20160607,20161205,EXP,,CA-JNJFOC-20160303360,JANSSEN,,34.0,YR,A,F,Y,,,20161205.0,,OT,CA,CA,2016,Q4,Young Adult
126111313,12611131,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,,100.0,MG,TABLET,QD,2016,Q4,Oedema peripheral,,2016,Q4,3,F,20160616.0,20160929.0,20160801,20161010,EXP,,JP-JNJFOC-20160723570,JANSSEN,,62.0,YR,A,M,Y,91.0,KG,20161010.0,,OT,JP,JP,2016,Q4,Adult
126111313,12611131,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,,100.0,MG,TABLET,QD,2016,Q4,Renal disorder,,2016,Q4,3,F,20160616.0,20160929.0,20160801,20161010,EXP,,JP-JNJFOC-20160723570,JANSSEN,,62.0,YR,A,M,Y,91.0,KG,20161010.0,,OT,JP,JP,2016,Q4,Adult
126111313,12611131,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Oedema peripheral,,2016,Q4,3,F,20160616.0,20160929.0,20160801,20161010,EXP,,JP-JNJFOC-20160723570,JANSSEN,,62.0,YR,A,M,Y,91.0,KG,20161010.0,,OT,JP,JP,2016,Q4,Adult
126111313,12611131,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Renal disorder,,2016,Q4,3,F,20160616.0,20160929.0,20160801,20161010,EXP,,JP-JNJFOC-20160723570,JANSSEN,,62.0,YR,A,M,Y,91.0,KG,20161010.0,,OT,JP,JP,2016,Q4,Adult
126689712,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Blood glucose abnormal,,2016,Q4,2,F,2016.0,20161206.0,20160819,20161212,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20161212.0,,MD,GB,GB,2016,Q4,Adult
126689712,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Diabetic ketoacidosis,,2016,Q4,2,F,2016.0,20161206.0,20160819,20161212,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20161212.0,,MD,GB,GB,2016,Q4,Adult
126689712,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Fatigue,,2016,Q4,2,F,2016.0,20161206.0,20160819,20161212,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20161212.0,,MD,GB,GB,2016,Q4,Adult
126689712,12668971,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Polydipsia,,2016,Q4,2,F,2016.0,20161206.0,20160819,20161212,EXP,,GB-JNJFOC-20160811677,JANSSEN,,63.0,YR,A,F,Y,86.0,KG,20161212.0,,MD,GB,GB,2016,Q4,Adult
128073851,12807385,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,,100.0,MG,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,,100.0,MG,TABLET,,2016,Q4,Drug prescribing error,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,,100.0,MG,TABLET,,2016,Q4,Off label use,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,,100.0,MG,TABLET,,2016,Q4,Weight decreased,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,150.0,MG,TABLET,QD,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,150.0,MG,TABLET,QD,2016,Q4,Drug prescribing error,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,150.0,MG,TABLET,QD,2016,Q4,Off label use,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073851,12807385,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,150.0,MG,TABLET,QD,2016,Q4,Weight decreased,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,CA-JNJFOC-20160930139,JANSSEN,"CLEMENT M, SENIOR P. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH CANAGLIFLOZIN: NOT-SO-SWEET BUT AVOIDABLE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR USE.. CANADIAN FAMILY PHYSICIAN 2016;62 (9):725-8.",42.0,YR,A,F,Y,,,20161004.0,,MD,CA,CA,2016,Q4,Adult
128073861,12807386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20160927.0,20161004,20161004,EXP,,US-JNJFOC-20160929806,JANSSEN,"TURNER J, BEGUM T, SMALLIGAN RD. CANAGLIFLOZIN-INDUCED DIABETIC KETOACIDOSIS: CASE REPORT AND REVIEW OF THE LITERATURE. JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS JUL-2016;4(3):1-3.",62.0,YR,A,F,Y,,,20161004.0,,OT,US,US,2016,Q4,Adult
128112671,12811267,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Penile infection,,2016,Q4,1,I,20160913.0,20160929.0,20161005,20161005,EXP,,GB-JNJFOC-20160929887,JANSSEN,,52.0,YR,A,M,Y,114.0,KG,20161005.0,,MD,GB,GB,2016,Q4,Adult
128112671,12811267,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Prostatitis,,2016,Q4,1,I,20160913.0,20160929.0,20161005,20161005,EXP,,GB-JNJFOC-20160929887,JANSSEN,,52.0,YR,A,M,Y,114.0,KG,20161005.0,,MD,GB,GB,2016,Q4,Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Abdominal pain,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Abdominal pain upper,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Alanine aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Aspartate aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Calculus bladder,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Cholecystitis,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Flatulence,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Nausea,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Ultrasound abdomen abnormal,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N, T229369;4373056,,204042.0,50.0,MG,TABLET,QD,2016,Q4,Vomiting,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Abdominal pain,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Abdominal pain upper,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Alanine aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Aspartate aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Calculus bladder,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Cholecystitis,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Flatulence,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Nausea,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Ultrasound abdomen abnormal,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,3,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N, T229369,,204353.0,,,TABLET,,2016,Q4,Vomiting,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Abdominal pain,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Abdominal pain upper,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Alanine aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Aspartate aminotransferase increased,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Calculus bladder,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Cholecystitis,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Flatulence,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Nausea,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Ultrasound abdomen abnormal,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128211702,12821170,4,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/500 MG,,,D,N, T229369,,110533.0,,,TABLET,,2016,Q4,Vomiting,,2016,Q4,2,F,20161001.0,20161007.0,20161007,20161014,PER,,US-JNJFOC-20161002401,JANSSEN,,24.0,YR,A,F,Y,81.0,KG,20161014.0,,MD,US,US,2016,Q4,Young Adult
128448561,12844856,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,STOPPED 8 MONTHS AGO,,,,N,,,,100.0,MG,TABLET,QD,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20161004.0,20161013,20161013,EXP,,CA-JNJFOC-20161004692,JANSSEN,"JAZI M, PORFIRIS G. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2 DIABETES TREATED WITH A SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR. CANADIAN FAMILY PHYSICIAN SEP-2016;62/9:722-724 AND E514-E51.",51.0,YR,A,M,Y,,,20161013.0,,MD,CA,CA,2016,Q4,Adult
128448561,12844856,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042,300.0,MG,TABLET,QD,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20161004.0,20161013,20161013,EXP,,CA-JNJFOC-20161004692,JANSSEN,"JAZI M, PORFIRIS G. EUGLYCEMIC DIABETIC KETOACIDOSIS IN TYPE 2 DIABETES TREATED WITH A SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR. CANADIAN FAMILY PHYSICIAN SEP-2016;62/9:722-724 AND E514-E51.",51.0,YR,A,M,Y,,,20161013.0,,MD,CA,CA,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Abdominal pain,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Acetonaemia,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Decreased appetite,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Dehydration,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Tachycardia,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Urine ketone body,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128450741,12845074,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,,2016,Q4,Vomiting,,2016,Q4,1,I,,20160930.0,20161013,20161013,EXP,,IN-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00448,SCIEGEN,,57.0,YR,,M,Y,,,20161013.0,,MD,IN,IN,2016,Q4,Adult
128517301,12851730,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20160930.0,,20161014,20161014,DIR,US-FDA-353261,,FDA-CTU,,54.0,YR,,F,N,60.0,KG,20161014.0,N,MD,US,US,2016,Q4,Adult
128547651,12854765,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2016,Q4,Glucose urine present,,2016,Q4,1,I,,20161012.0,20161017,20161017,EXP,,CA-BAYER-2016-199013,BAYER,,88.0,YR,E,M,Y,,,20161017.0,,MD,CA,CA,2016,Q4,Elderly
128547651,12854765,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2016,Q4,Ketonuria,,2016,Q4,1,I,,20161012.0,20161017,20161017,EXP,,CA-BAYER-2016-199013,BAYER,,88.0,YR,E,M,Y,,,20161017.0,,MD,CA,CA,2016,Q4,Elderly
128547651,12854765,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,,,,,,100.0,MG,,QD,2016,Q4,Glucose urine present,,2016,Q4,1,I,,20161012.0,20161017,20161017,EXP,,CA-BAYER-2016-199013,BAYER,,88.0,YR,E,M,Y,,,20161017.0,,MD,CA,CA,2016,Q4,Elderly
128547651,12854765,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,,,,,,100.0,MG,,QD,2016,Q4,Ketonuria,,2016,Q4,1,I,,20161012.0,20161017,20161017,EXP,,CA-BAYER-2016-199013,BAYER,,88.0,YR,E,M,Y,,,20161017.0,,MD,CA,CA,2016,Q4,Elderly
128582691,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Facial paralysis,,2016,Q4,1,I,20160312.0,20161007.0,20161018,20161018,EXP,,JP-JNJFOC-20161013100,JANSSEN,,39.0,YR,A,F,Y,86.0,KG,20161018.0,,OT,JP,JP,2016,Q4,Adult
128596162,12859616,4,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,QD,2016,Q4,Foot fracture,,2016,Q4,2,F,20161001.0,20161103.0,20161018,20161115,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-066370",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,94.0,KG,20161116.0,,MD,US,US,2016,Q4,Elderly
128596162,12859616,4,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,QD,2016,Q4,Fracture,,2016,Q4,2,F,20161001.0,20161103.0,20161018,20161115,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-066370",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,94.0,KG,20161116.0,,MD,US,US,2016,Q4,Elderly
128596162,12859616,4,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,QD,2016,Q4,Road traffic accident,,2016,Q4,2,F,20161001.0,20161103.0,20161018,20161115,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-066370",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,94.0,KG,20161116.0,,MD,US,US,2016,Q4,Elderly
128710631,12871063,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE WAS 300.0 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20160929.0,20161014.0,20161021,20161021,EXP,,GB-JNJFOC-20161013289,JANSSEN,,52.0,YR,A,F,Y,75.0,KG,20161021.0,,OT,GB,GB,2016,Q4,Adult
128763931,12876393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,300.0,MG,TABLET,QD,2016,Q4,Abdominal pain,,2016,Q4,1,I,20161003.0,20161017.0,20161024,20161024,EXP,,GB-JNJFOC-20161014433,JANSSEN,,63.0,YR,A,F,Y,65.0,KG,20161024.0,,PH,GB,GB,2016,Q4,Adult
128763931,12876393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,300.0,MG,TABLET,QD,2016,Q4,Confusional state,,2016,Q4,1,I,20161003.0,20161017.0,20161024,20161024,EXP,,GB-JNJFOC-20161014433,JANSSEN,,63.0,YR,A,F,Y,65.0,KG,20161024.0,,PH,GB,GB,2016,Q4,Adult
128763931,12876393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,300.0,MG,TABLET,QD,2016,Q4,Pyelonephritis acute,,2016,Q4,1,I,20161003.0,20161017.0,20161024,20161024,EXP,,GB-JNJFOC-20161014433,JANSSEN,,63.0,YR,A,F,Y,65.0,KG,20161024.0,,PH,GB,GB,2016,Q4,Adult
128848482,12884848,1,PS,CANAGLIFLOZIN/ METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,2,F,,20161114.0,20161026,20161128,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-126415,RANBAXY,"ANDREWS TJ, COX RD, PARKER C, KOLB J. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH ELEVATED ACETONE IN A PATIENT TAKING A SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR. J EMERG MED. 2016;OCT 4:EPUB AHEAD OF PRINT",57.0,YR,,F,Y,,,20161128.0,,OT,US,US,2016,Q4,Adult
128848482,12884848,1,PS,CANAGLIFLOZIN/ METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2016,Q4,Mental status changes,,2016,Q4,2,F,,20161114.0,20161026,20161128,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-126415,RANBAXY,"ANDREWS TJ, COX RD, PARKER C, KOLB J. EUGLYCEMIC DIABETIC KETOACIDOSIS WITH ELEVATED ACETONE IN A PATIENT TAKING A SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR. J EMERG MED. 2016;OCT 4:EPUB AHEAD OF PRINT",57.0,YR,,F,Y,,,20161128.0,,OT,US,US,2016,Q4,Adult
128856911,12885691,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q4,Confusional state,,2016,Q4,1,I,20160826.0,,20161025,20161025,DIR,,,FDA-CTU,,67.0,YR,,M,N,106.8,KG,20161018.0,N,PH,US,US,2016,Q4,Elderly
128856911,12885691,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2016,Q4,Urinary retention,,2016,Q4,1,I,20160826.0,,20161025,20161025,DIR,,,FDA-CTU,,67.0,YR,,M,N,106.8,KG,20161018.0,N,PH,US,US,2016,Q4,Elderly
128859791,12885979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Abdominal pain lower,,2016,Q4,1,I,20161006.0,20161018.0,20161026,20161026,EXP,,GB-JNJFOC-20161015694,JANSSEN,,63.0,YR,A,F,Y,62.0,KG,20161026.0,,MD,GB,GB,2016,Q4,Adult
128859791,12885979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20161006.0,20161018.0,20161026,20161026,EXP,,GB-JNJFOC-20161015694,JANSSEN,,63.0,YR,A,F,Y,62.0,KG,20161026.0,,MD,GB,GB,2016,Q4,Adult
128859791,12885979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Dizziness,,2016,Q4,1,I,20161006.0,20161018.0,20161026,20161026,EXP,,GB-JNJFOC-20161015694,JANSSEN,,63.0,YR,A,F,Y,62.0,KG,20161026.0,,MD,GB,GB,2016,Q4,Adult
128859791,12885979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Vulvovaginal candidiasis,,2016,Q4,1,I,20161006.0,20161018.0,20161026,20161026,EXP,,GB-JNJFOC-20161015694,JANSSEN,,63.0,YR,A,F,Y,62.0,KG,20161026.0,,MD,GB,GB,2016,Q4,Adult
128927261,12892726,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q4,Acute prerenal failure,,2016,Q4,1,I,20150618.0,,20161028,20161028,DIR,,,FDA-CTU,,80.0,YR,,F,N,71.8,KG,20160623.0,N,PH,US,US,2016,Q4,Elderly
128927261,12892726,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q4,Hypovolaemia,,2016,Q4,1,I,20150618.0,,20161028,20161028,DIR,,,FDA-CTU,,80.0,YR,,F,N,71.8,KG,20160623.0,N,PH,US,US,2016,Q4,Elderly
128927261,12892726,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2016,Q4,Polyuria,,2016,Q4,1,I,20150618.0,,20161028,20161028,DIR,,,FDA-CTU,,80.0,YR,,F,N,71.8,KG,20160623.0,N,PH,US,US,2016,Q4,Elderly
128934781,12893478,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 300; UNITS UNSPECIFIED,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Acidosis,,2016,Q4,1,I,,20161025.0,20161028,20161028,EXP,,GB-JNJFOC-20161022303,JANSSEN,,60.0,YR,A,F,Y,86.8,KG,20161028.0,,OT,GB,GB,2016,Q4,Adult
128934781,12893478,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 300; UNITS UNSPECIFIED,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Cardiac arrest,,2016,Q4,1,I,,20161025.0,20161028,20161028,EXP,,GB-JNJFOC-20161022303,JANSSEN,,60.0,YR,A,F,Y,86.8,KG,20161028.0,,OT,GB,GB,2016,Q4,Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Abnormal behaviour,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Balance disorder,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Blood creatine phosphokinase increased,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Blood pressure increased,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Blood urea increased,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Decreased appetite,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Hyperhidrosis,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Incontinence,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Infection,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Mental disorder,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Muscle rigidity,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Neuroleptic malignant syndrome,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Neutrophil count increased,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Pallor,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Personality change,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Pupillary reflex impaired,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Salivary hypersecretion,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Seizure,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Social avoidant behaviour,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Staring,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Tachycardia,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,Tremor,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
128981431,12898143,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,MORNING,,,D,,,,,100.0,DF,UNSPECIFIED,QD,2016,Q4,White blood cell count increased,,2016,Q4,1,I,20160929.0,20161028.0,20161031,20161031,EXP,,GB-JNJFOC-20161026124,JANSSEN,,29.0,YR,A,F,Y,,,20161031.0,,PH,GB,GB,2016,Q4,Young Adult
129042371,12904237,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,START DATE 8 MONTHS BEFORE PANCREATICODUODENECTOMY??STOP DATE ONE DAY BEFORE PANCREATICODUODENECTOMY,,,D,N,,,204042.0,,,TABLET,,2016,Q4,Ketoacidosis,,2016,Q4,1,I,,20161025.0,20161102,20161102,EXP,,CA-JNJFOC-20161024772,JANSSEN,"WOOD T, PANG A, HALLET J, GREIG P. EUGLYCAEMIC KETOACIDOSIS IN A POSTOPERATIVE WHIPPLE PATIENT USING CANAGLIFLOZIN. BMJ CASE REPORTS 2016;2016.",74.0,YR,E,M,Y,,,20161102.0,,OT,CA,CA,2016,Q4,Elderly
129094521,12909452,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2016,Q4,Neuroleptic malignant syndrome,,2016,Q4,1,I,20160930.0,20161026.0,20161104,20161104,EXP,,GB-ASTRAZENECA-2016SF13263,ASTRAZENECA,,29.0,YR,,F,Y,,,20161104.0,,PH,GB,GB,2016,Q4,Young Adult
129123031,12912303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Coronary artery stenosis,,2016,Q4,1,I,20160602.0,20161028.0,20161104,20161104,EXP,,JP-JNJFOC-20161102095,JANSSEN,,70.0,YR,E,M,Y,76.0,KG,20161104.0,,OT,JP,JP,2016,Q4,Elderly
129123111,12912311,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 300 (UNITS UNSPECIFIED).,,,,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20160916.0,20161027.0,20161104,20161104,EXP,,GB-JNJFOC-20161024973,JANSSEN,,53.0,YR,A,M,Y,110.0,KG,20161104.0,,MD,GB,GB,2016,Q4,Adult
129125721,12912572,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,300.0,MG,TABLET,,2016,Q4,Ketoacidosis,,2016,Q4,1,I,,20161027.0,20161104,20161104,EXP,,US-JNJFOC-20161027005,JANSSEN,"BOBART S, GLEASON B, MARTINEZ N, NORRIS K, WILLIAMS SF. EUGLYCEMIC KETOACIDOSIS CAUSED BY SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS: A CASE REPORT. ANN INTERN MED.",5.0,DEC,A,F,Y,,,20161104.0,,MD,US,US,2016,Q4,Child
129125742,12912574,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369874,,204042.0,,,CAPSULE,,2016,Q4,Osteomyelitis,,2016,Q4,2,F,20160711.0,20161026.0,20161104,20161109,EXP,,UA-JNJFOC-20160809521,JANSSEN,,51.0,YR,A,M,Y,92.0,KG,20161109.0,,MD,UA,UA,2016,Q4,Adult
129125742,12912574,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369874,,204042.0,,,CAPSULE,,2016,Q4,Toe amputation,,2016,Q4,2,F,20160711.0,20161026.0,20161104,20161109,EXP,,UA-JNJFOC-20160809521,JANSSEN,,51.0,YR,A,M,Y,92.0,KG,20161109.0,,MD,UA,UA,2016,Q4,Adult
129125742,12912574,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369874,,76479.0,300.0,MG,CAPSULE,QD,2016,Q4,Osteomyelitis,,2016,Q4,2,F,20160711.0,20161026.0,20161104,20161109,EXP,,UA-JNJFOC-20160809521,JANSSEN,,51.0,YR,A,M,Y,92.0,KG,20161109.0,,MD,UA,UA,2016,Q4,Adult
129125742,12912574,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N, 4369874,,76479.0,300.0,MG,CAPSULE,QD,2016,Q4,Toe amputation,,2016,Q4,2,F,20160711.0,20161026.0,20161104,20161109,EXP,,UA-JNJFOC-20160809521,JANSSEN,,51.0,YR,A,M,Y,92.0,KG,20161109.0,,MD,UA,UA,2016,Q4,Adult
129125751,12912575,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 100 (UNITS UNSPECIFIED).,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Liver injury,,2016,Q4,1,I,20160904.0,20161103.0,20161104,20161104,EXP,,GB-JNJFOC-20161103910,JANSSEN,,59.0,YR,A,F,Y,65.0,KG,20161104.0,,MD,GB,GB,2016,Q4,Adult
129246071,12924607,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q4,Abdominal pain,,2016,Q4,1,I,20161108.0,,20161108,20161108,DIR,US-FDA-355286,,FDA-CTU,,65.0,YR,,M,N,76.0,KG,20161108.0,N,PH,US,US,2016,Q4,Elderly
129246071,12924607,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q4,Fracture,,2016,Q4,1,I,20161108.0,,20161108,20161108,DIR,US-FDA-355286,,FDA-CTU,,65.0,YR,,M,N,76.0,KG,20161108.0,N,PH,US,US,2016,Q4,Elderly
129246071,12924607,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q4,Ketoacidosis,,2016,Q4,1,I,20161108.0,,20161108,20161108,DIR,US-FDA-355286,,FDA-CTU,,65.0,YR,,M,N,76.0,KG,20161108.0,N,PH,US,US,2016,Q4,Elderly
129246071,12924607,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q4,Nausea,,2016,Q4,1,I,20161108.0,,20161108,20161108,DIR,US-FDA-355286,,FDA-CTU,,65.0,YR,,M,N,76.0,KG,20161108.0,N,PH,US,US,2016,Q4,Elderly
129246071,12924607,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,QD,2016,Q4,Vomiting,,2016,Q4,1,I,20161108.0,,20161108,20161108,DIR,US-FDA-355286,,FDA-CTU,,65.0,YR,,M,N,76.0,KG,20161108.0,N,PH,US,US,2016,Q4,Elderly
129260551,12926055,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2016,Q4,Pancreatitis necrotising,,2016,Q4,1,I,,20161101.0,20161109,20161109,EXP,,US-JNJFOC-20161103543,JANSSEN,"PATEL K, ERIS P, TANYA G. DRUG-INDUCED NECROTIZING PANCREATITIS WITH A FOCUS ON CANAGLIFLOZIN. AM J GASTROENTEROL 2016;111:S557-S558.",71.0,YR,E,F,Y,,,20161109.0,,MD,US,US,2016,Q4,Elderly
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Abnormal behaviour,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Balance disorder,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Blood pressure increased,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Decreased appetite,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Hyperhidrosis,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Incontinence,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Mental disorder,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Muscle rigidity,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Neuroleptic malignant syndrome,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Pallor,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Personality change,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Pupillary reflex impaired,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Salivary hypersecretion,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Social avoidant behaviour,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Staring,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Tachycardia,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129264711,12926471,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY; MORNING,,,,,,,,100.0,MG,TABLET,QD,2016,Q4,Tremor,,2016,Q4,1,I,20160929.0,20161028.0,20161109,20161109,EXP,GB-MHRA-MIDB-4418B9D9-0D28-4544-A602-AEA8B1E494D3,GB-TEVA-709152ACC,TEVA,,29.0,YR,,F,Y,,,20161109.0,,PH,GB,GB,2016,Q4,Young Adult
129278011,12927801,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MG,,,,,,,,,,,,2016,Q4,Lactic acidosis,,2016,Q4,1,I,,20160720.0,20161109,20161109,PER,,JP-LUPIN PHARMACEUTICALS INC.-2016-03368,LUPIN,"GOCHO N, AOKI E, OKADA C, OMURA K, HIRASHIMA T, SUZUKI N, TANAKA H, OMORI Y. NON-OCCLUSIVE MESENTERIC ISCHEMIA WITH DIABETIC KETOACIDOSIS AND LACTIC ACIDOSIS FOLLOWING THE ADMINISTRATION OF A SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITOR. INTERNAL MEDICINE. 2016;55:1755-1760.",60.0,YR,,M,Y,72.8,KG,20161108.0,,MD,JP,JP,2016,Q4,Adult
129547691,12954769,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 300 UNITS UNSPECIFIED.,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20161105.0,20161116.0,20161118,20161118,EXP,,GB-JNJFOC-20161117618,JANSSEN,,30.0,YR,A,F,Y,80.0,KG,20161118.0,,MD,GB,GB,2016,Q4,Young Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Arthralgia,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Carpal tunnel syndrome,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Cataract,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Diabetes mellitus inadequate control,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Diabetic neuropathy,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Drug hypersensitivity,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Dysmenorrhoea,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Gastrooesophageal reflux disease,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Hyperlipidaemia,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Hypertension,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Intervertebral disc degeneration,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Joint contracture,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Menometrorrhagia,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Obesity,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Pelvic pain,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Plantar fasciitis,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Rhinitis allergic,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Sciatica,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Seborrhoeic keratosis,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129572111,12957211,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, QD",,,,,,,,1.0,DF,,QD,2016,Q4,Tooth erosion,,2016,Q4,1,I,,20161114.0,20161118,20161118,EXP,,US-BAYER-2016-219107,BAYER,,59.0,YR,A,F,Y,,,20161118.0,,CN,US,US,2016,Q4,Adult
129870241,12987024,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,TABLET,,2016,Q4,Ketosis,,2016,Q4,1,I,20161106.0,20161122.0,20161130,20161130,EXP,,IT-JNJFOC-20161123791,JANSSEN,,57.0,YR,A,M,Y,,,20161130.0,,MD,IT,IT,2016,Q4,Adult
129906671,12990667,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,100.0,MG,,QD,2016,Q4,Pancreatitis acute,,2016,Q4,1,I,20160829.0,,20161130,20161130,DIR,,,FDA-CTU,,76.0,YR,,M,N,97.6,KG,20160831.0,N,PH,US,US,2016,Q4,Elderly
129910781,12991078,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,U,,,,100.0,MG,,,2016,Q4,Orthostatic hypotension,,2016,Q4,1,I,20161012.0,20161129.0,20161201,20161201,EXP,GB-MHRA-ADR 23741778,GB-TAKEDA-2016TEU005941,TAKEDA,,49.0,YR,,M,Y,116.0,KG,20161201.0,,OT,GB,GB,2016,Q4,Adult
129976571,12997657,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1000 MG, UNK",,,,,,,,1000.0,MG,TABLET,,2016,Q4,Fatigue,,2016,Q4,1,I,201611.0,20161202.0,20161205,20161205,PER,,US-BEH-2016075756,CSL BEHRING,,58.0,YR,A,F,Y,,,20161205.0,,MD,US,US,2016,Q4,Adult
129976571,12997657,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1000 MG, UNK",,,,,,,,1000.0,MG,TABLET,,2016,Q4,Insomnia,,2016,Q4,1,I,201611.0,20161202.0,20161205,20161205,PER,,US-BEH-2016075756,CSL BEHRING,,58.0,YR,A,F,Y,,,20161205.0,,MD,US,US,2016,Q4,Adult
129976571,12997657,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1000 MG, UNK",,,,,,,,1000.0,MG,TABLET,,2016,Q4,Malaise,,2016,Q4,1,I,201611.0,20161202.0,20161205,20161205,PER,,US-BEH-2016075756,CSL BEHRING,,58.0,YR,A,F,Y,,,20161205.0,,MD,US,US,2016,Q4,Adult
129976571,12997657,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1000 MG, UNK",,,,,,,,1000.0,MG,TABLET,,2016,Q4,Nocturia,,2016,Q4,1,I,201611.0,20161202.0,20161205,20161205,PER,,US-BEH-2016075756,CSL BEHRING,,58.0,YR,A,F,Y,,,20161205.0,,MD,US,US,2016,Q4,Adult
129976571,12997657,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1000 MG, UNK",,,,,,,,1000.0,MG,TABLET,,2016,Q4,Swelling,,2016,Q4,1,I,201611.0,20161202.0,20161205,20161205,PER,,US-BEH-2016075756,CSL BEHRING,,58.0,YR,A,F,Y,,,20161205.0,,MD,US,US,2016,Q4,Adult
129986031,12998603,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,D,D,,,,,,,,2016,Q4,Fasciitis,,2016,Q4,1,I,20161108.0,,20161204,20161204,DIR,US-FDA-357259,,FDA-CTU,,43.0,YR,,F,N,102.6,KG,20161204.0,N,PH,US,US,2016,Q4,Adult
129986031,12998603,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,D,D,,,,,,,,2016,Q4,Necrosis,,2016,Q4,1,I,20161108.0,,20161204,20161204,DIR,US-FDA-357259,,FDA-CTU,,43.0,YR,,F,N,102.6,KG,20161204.0,N,PH,US,US,2016,Q4,Adult
129986031,12998603,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,D,D,,,,,,,,2016,Q4,Vulval abscess,,2016,Q4,1,I,20161108.0,,20161204,20161204,DIR,US-FDA-357259,,FDA-CTU,,43.0,YR,,F,N,102.6,KG,20161204.0,N,PH,US,US,2016,Q4,Adult
129986641,12998664,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Acute coronary syndrome,,2016,Q4,1,I,20160701.0,20161128.0,20161205,20161205,EXP,,JP-JNJFOC-20161204097,JANSSEN,,73.0,YR,E,M,Y,64.0,KG,20161205.0,,OT,JP,JP,2016,Q4,Elderly
130020601,13002060,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,TABLET,,2016,Q4,Gastric cancer,,2016,Q4,1,I,201610.0,20161128.0,20161206,20161206,EXP,,JP-JNJFOC-20161204145,JANSSEN,,8.0,DEC,E,M,Y,,,20161206.0,,OT,JP,JP,2016,Q4,Child
130061541,13006154,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,23800.0,MG,N,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Confusional state,,2016,Q4,1,I,20161107.0,20161129.0,20161207,20161207,EXP,,GB-JNJFOC-20161129927,JANSSEN,,57.0,YR,A,F,Y,,,20161207.0,,PH,GB,GB,2016,Q4,Adult
130061541,13006154,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,23800.0,MG,N,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Depression,,2016,Q4,1,I,20161107.0,20161129.0,20161207,20161207,EXP,,GB-JNJFOC-20161129927,JANSSEN,,57.0,YR,A,F,Y,,,20161207.0,,PH,GB,GB,2016,Q4,Adult
130061541,13006154,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,23800.0,MG,N,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Hyponatraemia,,2016,Q4,1,I,20161107.0,20161129.0,20161207,20161207,EXP,,GB-JNJFOC-20161129927,JANSSEN,,57.0,YR,A,F,Y,,,20161207.0,,PH,GB,GB,2016,Q4,Adult
130061541,13006154,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,23800.0,MG,N,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Urinary incontinence,,2016,Q4,1,I,20161107.0,20161129.0,20161207,20161207,EXP,,GB-JNJFOC-20161129927,JANSSEN,,57.0,YR,A,F,Y,,,20161207.0,,PH,GB,GB,2016,Q4,Adult
130156091,13015609,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q4,Haematuria,,2016,Q4,1,I,,20161117.0,20161212,20161212,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-084578",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,,,20161210.0,,OT,GB,GB,2016,Q4,Adult
130227961,13022796,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Pruritus,,2016,Q4,1,I,20161102.0,20161208.0,20161213,20161213,EXP,,GB-JNJFOC-20161208712,JANSSEN,,51.0,YR,A,F,Y,95.25,KG,20161213.0,,CN,GB,GB,2016,Q4,Adult
130227961,13022796,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Urine output increased,,2016,Q4,1,I,20161102.0,20161208.0,20161213,20161213,EXP,,GB-JNJFOC-20161208712,JANSSEN,,51.0,YR,A,F,Y,95.25,KG,20161213.0,,CN,GB,GB,2016,Q4,Adult
130227961,13022796,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Vaginal haemorrhage,,2016,Q4,1,I,20161102.0,20161208.0,20161213,20161213,EXP,,GB-JNJFOC-20161208712,JANSSEN,,51.0,YR,A,F,Y,95.25,KG,20161213.0,,CN,GB,GB,2016,Q4,Adult
130227961,13022796,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Vulvovaginal candidiasis,,2016,Q4,1,I,20161102.0,20161208.0,20161213,20161213,EXP,,GB-JNJFOC-20161208712,JANSSEN,,51.0,YR,A,F,Y,95.25,KG,20161213.0,,CN,GB,GB,2016,Q4,Adult
130299161,13029916,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CUMULATIVE DOSE TO FIRST REACTION: 309.958333,,,D,N,,,204042.0,1.0,DF,TABLET,QD,2016,Q4,Cellulitis,,2016,Q4,1,I,20160915.0,20161208.0,20161215,20161215,EXP,,GB-JNJFOC-20161208740,JANSSEN,,69.0,YR,E,M,Y,70.0,KG,20161215.0,,PH,GB,GB,2016,Q4,Elderly
130299161,13029916,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CUMULATIVE DOSE TO FIRST REACTION: 309.958333,,,D,N,,,204042.0,1.0,DF,TABLET,QD,2016,Q4,Neuropathic arthropathy,,2016,Q4,1,I,20160915.0,20161208.0,20161215,20161215,EXP,,GB-JNJFOC-20161208740,JANSSEN,,69.0,YR,E,M,Y,70.0,KG,20161215.0,,PH,GB,GB,2016,Q4,Elderly
130299161,13029916,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CUMULATIVE DOSE TO FIRST REACTION: 309.958333,,,D,N,,,204042.0,1.0,DF,TABLET,QD,2016,Q4,Paronychia,,2016,Q4,1,I,20160915.0,20161208.0,20161215,20161215,EXP,,GB-JNJFOC-20161208740,JANSSEN,,69.0,YR,E,M,Y,70.0,KG,20161215.0,,PH,GB,GB,2016,Q4,Elderly
130341581,13034158,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q4,Altered state of consciousness,,2016,Q4,1,I,20160725.0,20161208.0,20161216,20161216,EXP,,GB-JNJFOC-20161208748,JANSSEN,,48.0,YR,A,F,Y,74.0,KG,20161216.0,,MD,GB,GB,2016,Q4,Adult
130341581,13034158,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2016,Q4,Hyperosmolar hyperglycaemic state,,2016,Q4,1,I,20160725.0,20161208.0,20161216,20161216,EXP,,GB-JNJFOC-20161208748,JANSSEN,,48.0,YR,A,F,Y,74.0,KG,20161216.0,,MD,GB,GB,2016,Q4,Adult
130360211,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2016,Q4,Cholecystitis acute,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130360211,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2016,Q4,Cholelithiasis,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130360211,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2016,Q4,Pancreatitis,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130360211,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Cholecystitis acute,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130360211,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Cholelithiasis,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130360211,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Pancreatitis,,2016,Q4,1,I,20160710.0,20161205.0,20161216,20161216,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20161216.0,,OT,JP,JP,2016,Q4,Adult
130367881,13036788,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q4,Bladder cancer,,2016,Q4,1,I,,20161117.0,20161216,20161216,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-085828",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,,,20161216.0,,OT,GB,GB,2016,Q4,Adult
130367881,13036788,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,U,,,,,,,,2016,Q4,Haematuria,,2016,Q4,1,I,,20161117.0,20161216,20161216,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-085828",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,,,20161216.0,,OT,GB,GB,2016,Q4,Adult
130373461,13037346,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,Y,,,,,100.0,MG,TABLET,QD,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20160819.0,20161202.0,20161216,20161216,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-105735,BRISTOL MYERS SQUIBB,,65.0,YR,,F,Y,114.0,KG,20161216.0,,CN,GB,GB,2016,Q4,Elderly
130458861,13045886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2016,Q4,Haematuria,,2016,Q4,1,I,,20161213.0,20161220,20161220,EXP,,GB-JNJFOC-20161214111,JANSSEN,,49.0,YR,A,F,Y,,,20161220.0,,OT,US,GB,2016,Q4,Adult
130489862,13048986,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STARTED ONE YEAR AGO,,,,N, UNKNOWN,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,2,F,,20161222.0,20161221,20161228,EXP,,US-JNJFOC-20161213125,JANSSEN,"ULLAH S, KHAN N, ZEB H, TAHIR H. METABOLIC KETOACIDOSIS WITH NORMAL BLOOD GLUCOSE: A RARE COMPLICATION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS.. SAGE OPEN MEDICAL CASE REPORTS 2016;4:1-3.",40.0,YR,A,F,Y,,,20161228.0,,MD,US,US,2016,Q4,Adult
130546712,13054671,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Rash pustular,,2016,Q4,2,F,20161126.0,20161215.0,20161222,20161223,EXP,,IT-JNJFOC-20161213530,JANSSEN,,67.0,YR,E,F,Y,86.0,KG,20161223.0,,MD,IT,IT,2016,Q4,Elderly
130557911,13055791,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,,,CAPSULE,,2016,Q4,Cardiac failure,,2016,Q4,1,I,20161129.0,20161214.0,20161222,20161222,EXP,,CA-JNJFOC-20161212681,JANSSEN,,60.0,YR,A,F,Y,106.0,KG,20161222.0,,MD,CA,CA,2016,Q4,Adult
130557911,13055791,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,76479.0,300.0,MG,CAPSULE,QD,2016,Q4,Cardiac failure,,2016,Q4,1,I,20161129.0,20161214.0,20161222,20161222,EXP,,CA-JNJFOC-20161212681,JANSSEN,,60.0,YR,A,F,Y,106.0,KG,20161222.0,,MD,CA,CA,2016,Q4,Adult
130582711,13058271,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B186325,,204042.0,,,CAPSULE,,2016,Q4,Chest pain,,2016,Q4,1,I,201608.0,20161214.0,20161223,20161223,EXP,,US-JNJFOC-20161213278,JANSSEN,,62.0,YR,A,M,Y,108.0,KG,20161223.0,,MD,US,US,2016,Q4,Adult
130582711,13058271,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, B186325,,76479.0,300.0,MG,CAPSULE,QD,2016,Q4,Chest pain,,2016,Q4,1,I,201608.0,20161214.0,20161223,20161223,EXP,,US-JNJFOC-20161213278,JANSSEN,,62.0,YR,A,M,Y,108.0,KG,20161223.0,,MD,US,US,2016,Q4,Adult
130582731,13058273,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20161222.0,20161223,20161223,EXP,,GB-JNJFOC-20161219658,JANSSEN,,84.0,YR,E,M,Y,,,20161223.0,,PH,GB,GB,2016,Q4,Elderly
130592971,13059297,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2016,Q4,Ketosis,,2016,Q4,1,I,20161206.0,20161216.0,20161223,20161223,EXP,,GB-JNJFOC-20161215391,JANSSEN,,57.0,YR,A,M,Y,,,20161223.0,,MD,GB,GB,2016,Q4,Adult
130647981,13064798,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Myasthenia gravis,,2016,Q4,1,I,20161205.0,20161223.0,20161227,20161227,EXP,,GB-JNJFOC-20161221267,JANSSEN,,84.0,YR,E,F,Y,69.5,KG,20161227.0,,MD,GB,GB,2016,Q4,Elderly
130648101,13064810,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 (UNITS UNSPECIFIED),,,N,N,,,204042.0,,,TABLET,,2016,Q4,Inappropriate schedule of drug administration,,2016,Q4,1,I,201511.0,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161218415,JANSSEN,,62.0,YR,A,M,Y,89.0,KG,20161227.0,,MD,GB,GB,2016,Q4,Adult
130648101,13064810,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 (UNITS UNSPECIFIED),,,N,N,,,204042.0,,,TABLET,,2016,Q4,Muscle atrophy,,2016,Q4,1,I,201511.0,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161218415,JANSSEN,,62.0,YR,A,M,Y,89.0,KG,20161227.0,,MD,GB,GB,2016,Q4,Adult
130648101,13064810,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 (UNITS UNSPECIFIED),,,N,N,,,204042.0,,,TABLET,,2016,Q4,Muscular weakness,,2016,Q4,1,I,201511.0,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161218415,JANSSEN,,62.0,YR,A,M,Y,89.0,KG,20161227.0,,MD,GB,GB,2016,Q4,Adult
130648101,13064810,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,DOSE: 100 (UNITS UNSPECIFIED),,,N,N,,,204042.0,,,TABLET,,2016,Q4,Off label use,,2016,Q4,1,I,201511.0,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161218415,JANSSEN,,62.0,YR,A,M,Y,89.0,KG,20161227.0,,MD,GB,GB,2016,Q4,Adult
130648111,13064811,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,TABLET,,2016,Q4,Bladder cancer,,2016,Q4,1,I,,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161217838,JANSSEN,,49.0,YR,A,F,Y,,,20161227.0,,OT,GB,GB,2016,Q4,Adult
130648111,13064811,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,,,TABLET,,2016,Q4,Haematuria,,2016,Q4,1,I,,20161220.0,20161227,20161227,EXP,,GB-JNJFOC-20161217838,JANSSEN,,49.0,YR,A,F,Y,,,20161227.0,,OT,GB,GB,2016,Q4,Adult
130681681,13068168,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,20161213.0,20161222.0,20161228,20161228,EXP,,GB-JNJFOC-20161219797,JANSSEN,,68.0,YR,E,F,Y,86.0,KG,20161228.0,,MD,GB,GB,2016,Q4,Elderly
130681681,13068168,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2016,Q4,Sepsis,,2016,Q4,1,I,20161213.0,20161222.0,20161228,20161228,EXP,,GB-JNJFOC-20161219797,JANSSEN,,68.0,YR,E,F,Y,86.0,KG,20161228.0,,MD,GB,GB,2016,Q4,Elderly
130741521,13074152,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2016,Q4,Influenza like illness,,2016,Q4,1,I,20161024.0,20161220.0,20161230,20161230,EXP,,US-ROCHE-1870521,ROCHE,,50.0,YR,,F,Y,,,20161230.0,,MD,US,US,2016,Q4,Adult
130756521,13075652,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STARTED TWO WEEKS PRIOR TO HOSPITAL ADMISSION,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Diabetic ketoacidosis,,2016,Q4,1,I,,20161227.0,20161230,20161230,EXP,,US-JNJFOC-20161224302,JANSSEN,"JIANG C, PALKAR A, CARONIA J, GOTTESMAN E. SGLT2 INHIBITORS: MIND THE GAP. CHEST OCT-2016;150 (4 SUPPLEMENT 1):266A.",20.0,YR,A,F,Y,,,20161230.0,,MD,US,US,2016,Q4,Youth
130756521,13075652,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STARTED TWO WEEKS PRIOR TO HOSPITAL ADMISSION,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Glycosuria,,2016,Q4,1,I,,20161227.0,20161230,20161230,EXP,,US-JNJFOC-20161224302,JANSSEN,"JIANG C, PALKAR A, CARONIA J, GOTTESMAN E. SGLT2 INHIBITORS: MIND THE GAP. CHEST OCT-2016;150 (4 SUPPLEMENT 1):266A.",20.0,YR,A,F,Y,,,20161230.0,,MD,US,US,2016,Q4,Youth
130756521,13075652,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STARTED TWO WEEKS PRIOR TO HOSPITAL ADMISSION,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Off label use,,2016,Q4,1,I,,20161227.0,20161230,20161230,EXP,,US-JNJFOC-20161224302,JANSSEN,"JIANG C, PALKAR A, CARONIA J, GOTTESMAN E. SGLT2 INHIBITORS: MIND THE GAP. CHEST OCT-2016;150 (4 SUPPLEMENT 1):266A.",20.0,YR,A,F,Y,,,20161230.0,,MD,US,US,2016,Q4,Youth
130756521,13075652,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,STARTED TWO WEEKS PRIOR TO HOSPITAL ADMISSION,,,U,U,,,204042.0,,,TABLET,,2016,Q4,Product use issue,,2016,Q4,1,I,,20161227.0,20161230,20161230,EXP,,US-JNJFOC-20161224302,JANSSEN,"JIANG C, PALKAR A, CARONIA J, GOTTESMAN E. SGLT2 INHIBITORS: MIND THE GAP. CHEST OCT-2016;150 (4 SUPPLEMENT 1):266A.",20.0,YR,A,F,Y,,,20161230.0,,MD,US,US,2016,Q4,Youth
